Patent Grant
10052037
Prolonged reduction or loss of blood pressure in a patient severely limits the amount of tissue perfusion of the patient and therefore causes damage to or death of the tissue. Although some tissues can tolerate hypoperfusion for long periods of time, the brain, heart and kidneys are very sensitive to a reduction in blood flow. Thus, during and after medical procedures and at other times, blood pressure is a frequently monitored vital sign. Blood pressure can be affected by the type of medical procedure performed and by physiological factors such as the body's reaction to the medical procedure. Moreover, blood pressure is often manipulated and controlled using various medications. Medical procedures, physiological factors, and medications can cause the blood pressure of a patient to change rapidly.
The traditional method of measuring blood pressure is with a stethoscope, occlusive cuff, and pressure manometer. Blood pressure cuff instruments make only a spot-check measurement, so repetitive interval measurements are often used to trend patient status. More frequent intervals improve vigilance at the expense of patient discomfort, possible patient injury (e.g., due to occlusion of blood vessels), and excessive battery consumption.
In certain embodiments, a method of monitoring blood pressure of a patient includes receiving a physiological electrical signal from an electrical sensor coupled with a patient. The physiological electrical signal can reflect electrical activity of the patient's heart. The method may also include receiving a cardiac ejection signal from a second sensor coupled with the patient. This cardiac ejection signal can reflect a cardiac ejection event associated with ejection of blood from the patient's heart. In addition, the method may include receiving an arterial pulse signal from a third sensor coupled with a limb of the patient. The method can also include determining an arterial pulse wave transit time (PWTT) that compensates for a pre-ejection period of a cardiac cycle associated with the patient's heart, based at least partly on the physiological electrical signal, the cardiac ejection signal, and the arterial pulse signal. Moreover, the method may include triggering an occlusive blood pressure cuff to obtain a blood pressure measurement from the patient responsive to a change in the arterial PWTT.
For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the inventions have been described herein. It is to be understood that not necessarily all such advantages can be achieved in accordance with any particular embodiment of the inventions disclosed herein. Thus, the inventions disclosed herein can be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other advantages as can be taught or suggested herein.
Throughout the drawings, reference numbers can be re-used to indicate correspondence between referenced elements. The drawings are provided to illustrate embodiments of the inventions described herein and not to limit the scope thereof.
The propagation time of an arterial pulse wave from the heart to an extremity is related to blood pressure. Currently available blood pressure monitoring systems estimate this propagation time by detecting a time difference between points on an electrocardiograph (ECG) waveform and a photoplethysmograph waveform. This estimated propagation time is sometimes referred to as pulse wave transit time (PWTT) or time difference of arrival (TDOA). Currently available blood pressure monitoring systems trigger an automatic occlusive cuff to take a blood pressure measurement based on detected changes in PWTT. When the PWTT has not changed substantially, the blood pressure monitoring system usually does not trigger an occlusive blood pressure measurement. As a result, such a system automatically adjusts the frequency of occlusive blood pressure measurements to obtain better data while potentially reducing discomfort for the patient.
A drawback with existing blood pressure systems is that PWTT as calculated by these systems is not always an accurate indicator of blood pressure or changes in blood pressure. One reason for this inaccuracy is that currently-available systems do not account for a patient's pre-ejection period (PEP) when computing PWTT. The PEP can include the difference in time between an electrical trigger that initiates ventricular contraction (e.g., as detected by an ECG sensor) and the actual ejection of blood from the ventricles into the aorta. Accordingly, the calculated PWTT does not accurately represent the actual propagation time of the arterial pulse from the heart to an extremity, which can result in inaccuracy in the blood pressure variability measurements.
Another reason for the inaccuracy of existing blood pressure systems is that the photoplethysmograph waveform is typically obtained from an optical sensor coupled to a finger of the patient. Studies have shown that pulse wave velocity slows greatly at the transition from the arteries to the smaller vessels and capillaries, adding considerable delay to the arterial PWTT. This time delay can account for up to 50% of the arterial PWTT. The use of an acoustic sensor positioned over an artery to monitor arterial pulse instead of capillary flow can advantageously remove the effect of the artery-to-capillary transition delay component of the arterial pulse wave transit time measurements.
This disclosure describes, among other features, a system for non-invasively determining an indication of an individual's blood pressure. In certain embodiments, the system dynamically accounts for a patient's PEP when calculating PWTT. The system can include an optical sensor that obtains plethysmograph information from a patient. The system can further include an electrical sensor, which can be any sensor that obtains information relating to the electrical activity of the patient's heart (such as an ECG sensor). In addition, the system can include another sensor, such as an acoustic sensor or a bioimpedance sensor, which can obtain information about cardiac ejections from the patient's heart. In certain embodiments, the system further includes a processor that calculates PWTT compensated for PEP using the information obtained from the optical, electrical, acoustic, and/or bioimpedance sensors. The system can use this compensated PWTT to determine whether to trigger an occlusive cuff measurement.
In some embodiments, the system determines an arterial pulse wave transit time measurement from features of two acoustic waveforms. The system can include an acoustic heart sounds sensor that obtains heart sound information from a patient. The system can further include an acoustic pulse sensor, which can be placed at a location remote from the patient's heart at which peripheral arterial pulse pressure wave vibrations can be monitored (such as at a patient's wrist or neck). In addition, the system can include one or more other sensors, such as a second acoustic pulse sensor, ECG sensors, optical sensors, and/or bioimpedance sensors. In certain embodiments, the system further includes a processor that calculates arterial PWTT using the information obtained from the acoustic and/or other sensors. The system can use the arterial PWTT measurements to estimate changes in blood pressure and to aid in determining whether to trigger an occlusive cuff measurement.
In some embodiments, the system also compensates PWTT data for noise. For example, the system can use a noise reference signal to reduce noise in the PWTT data. The noise reference signal can be derived from the patient's heart rate. The system can reduce noise in the PWTT, for example, by adaptively reducing the noise based on the noise reference signal or by dynamically adjusting an averaging time used to average the PWTT data, among other possible techniques.
Moreover, in certain embodiments, the non-invasive blood pressure measurement system also calibrates PWTT data based on an individualized patient calibration factor. A calibration function or curve can be determined that maps PWTT measurements to blood pressure values. The slope of the calibration curve can be determined experimentally and can vary greatly from patient to patient. In some embodiments, the system determines an individualized, or personalized, patient calibration factor based on the determined slope. The patient calibration factor can then be used to interpret subsequent PWTT measurements to estimate changes in blood pressure. The individualized patient calibration can advantageously reduce the occurrence of unnecessary blood pressure cuff measurements and/or false alarms.
System Overview
In the depicted embodiment, the parameter calculation system 100 includes a parameter calculator 110 and a display 120. The parameter calculator 110 can include hardware (such as one or more processors), software, and/or firmware for measuring a physiological parameter such as blood pressure. Inputs to the parameter calculator 110 can include, among others, optical sensor data provided by an optical sensor 102, acoustic sensor data provided by one or more acoustic sensors 104, and/or additional sensor data provided by one or more additional sensors 106. The optical sensor 102 can be a pulse oximetry sensor, a co-oximetry sensor, or the like. The acoustic sensors 104 can be biological sound sensors. The biological sounds may include heart, breathing, and/or digestive system sounds, in addition to many other physiological phenomena. The additional sensors 106 can include any sensing device that provides physiological data to the parameter calculator 110. For example, the additional sensors 106 can include an electrical sensor configured to provide an ECG signal, an acoustic sensor, and/or a bioimpedance sensor, or any other sensing device.
The optical sensor 102 can use spectrophotometry techniques to measure a variety of blood constituents, including for example, oxygen saturation, hemoglobin, methemoglobin, carboxyhemoglobin, other hemoglobin species, concentrations of the same, and the like. In addition, the optical sensor 102 can also be used to measure a variety of other physiological parameters, including pulse rate, perfusion, and the like. The optical sensor 102 can include one or more emitters that shine one or more wavelengths of light through tissue of a living person, such as through a finger, toe, or foot. One or more detectors can receive the transmitted light after attenuation by the tissue and can generate one or more signals responsive to the attenuated light.
In certain embodiments, the parameter calculator 110 derives a photoplethysmograph from the optical sensor data The photoplethysmograph (sometimes referred to herein as a “plethysmograph,” “photopleth” or “pleth”) can be a waveform that can represent changes in blood volume as measured by one or more wavelengths of light irradiated at a tissue site of a patient. The photoplethysmograph can be caused by arterial pulsation, and as such, can be related to arterial blood pressure. Thus, in some embodiments, the parameter calculator 110 uses the optical sensor data to derive an indication of blood pressure for a patient.
In one embodiment, the parameter calculator 110 can use the optical sensor data and the additional sensor data 106 to derive one or more indications of blood pressure. For example, a combination of the optical sensor data and data from electrical sensor(s), acoustic sensor(s) 104, and/or bioimpedance sensors(s) can be used to determine an amount of time that it takes for a pulse to travel through an artery from a patient's heart to a measurement site. This time can be referred to as an arterial pulse-wave transit time (a-PWTT). Advantageously, in certain embodiments, the parameter calculator 110 can more accurately determine the a-PWTT based at least in part on the additional sensor data 106 obtained from an acoustic (104) and/or bioimpedance sensor. In particular, using the additional sensor data 106, the parameter calculator 110 can account for a patient's cardiac pre-ejection period (PEP) when calculating a-PWTT. In other embodiments, the parameter calculator 110 uses the acoustic sensor data derived from acoustic sensors 104 alone to derive one or more indications of blood pressure. Using the estimated changes in blood pressure, the parameter calculator 110 can trigger a blood pressure cuff 108 to obtain an occlusive blood pressure measurement.
The parameter calculator 110 can output parameter data 113 indicative of the calculated parameters, including blood pressure, for presentation to a user. The parameter data 113 can be displayed on a display device 120. In another embodiment, the parameter calculator 110 provides parameter values as an output 112 to another device, for example, a device providing an audible response, or over a network to a remote device. For example, a remote device might be a computer located at a nurses' station or a clinician's handheld device.
The parameter calculator 110 can also calculate trend data reflecting trend information for the parameter data 113. The parameter calculator 110 can also synthesize or scale waveform data. In addition to outputting the parameter data 113, the parameter calculator 110 can output trend data 114, synthesized, scaled, or actual waveforms 115, calibration data 116, and alarms 117. The parameter calculator 110 can provide the outputs 113, 114, 115, 116 to the display 120, to a separate patient monitoring device, or to another device configured to receive physiological parameter information.
In an embodiment, the parameter calculator 110 is implemented in a single monitoring device. In an embodiment, the features of the parameter calculator 110 are distributed among separate devices. In an embodiment, the parameter calculator 110 includes a processor, processor board, or an Original Equipment Manufacture (OEM) board. In an embodiment, the parameter calculator 110 is portable. Data communicated between the various components of the parameter calculation system 100 can be communicated through cables or wirelessly. Other inputs and/or outputs can be included with the system 100.
The display 120 of the parameter calculation system 100 can be part of a patient monitor (not shown), which can also include other components, such as a speaker, power button, removable storage or memory (e.g., a flash card slot), an AC power port, and one or more network interfaces, such as a universal serial bus interface or an Ethernet port. The display 120 can indicate a measurement for blood pressure, for example, a measurement of the systolic and diastolic blood pressure in mmHg. Other physiological parameter values, waveforms, trend data, calibration data, alarms, and the like can also be output on the display 120.
Although the parameter calculator 110 is described as calculating changes in blood pressure, in some embodiments, the parameter calculator 110 calculates actual blood pressure values from the acoustic and/or additional sensor data. In addition, the parameter calculation system 100 can also measure other physiological parameters besides blood pressure, such as pulse rate, oxygen saturation (SpO2), hemoglobin, total hemoglobin, hemoglobin species (e.g., methemoglobin, carboxyhemoglobin, or the like), carbon monoxide or dioxide, perfusion, and glucose, among a variety of other parameters.
Further, in some embodiments, the parameter calculator 110 uses acoustic sensor data (from the acoustic sensor(s) 104) to determine any of a variety of respiratory parameters of a patient, including respiratory rate, inspiratory time, expiratory time, inspiratory to expiratory (I:E) ratio, inspiratory flow, expiratory flow, tidal volume, minute volume, apnea duration, hypopnea duration, breath sounds (e.g., rales, rhonchi, and stridor), and changes in breath sounds such as decreased volume or change in airflow (either increase or decrease). In addition, in some cases the parameter calculator 110 monitors other physiological sounds from the acoustic sensor 104 data, such as heart rate (e.g., to help with probe off detection), heart sounds (S1, S2, S3, S4, and murmurs), and change in heart sounds such as normal to murmur or split heart sounds indicating fluid overload. Moreover, a second acoustic sensor 104 may be placed over the chest for better heart sound detection. The parameter calculator 110 may keep user inputs to a minimum (example, height) and use a Health Level 7 (HL7) interface to automatically input patient demography.
Example PWTT Calculations
The plethysmograph waveform 210 can reflect changes in pulsatile flow of blood in body tissue of a patient. The ECG waveform 220 can reflect electrical activity of a patient's heart. The ECG waveform 220 can have features including, for example, a Q-wave, an R-wave peak, and an S-wave, among others. A segment of the ECG waveform 220 from the Q point to the S point can be referred to as a QRS complex, which can represent ventricular activation.
Velocity of a blood pressure wave in the arteries has a correlation with blood pressure. As the length of an artery is typically constant or approximately constant, the time that it takes for the blood pressure wave to travel from the heart to an extremity can be used to derive an indication of blood pressure. In currently available monitoring systems, a measure of such time, referred to as PWTT, has been used to infer changes in blood pressure. In some embodiments, the PWTT can represent a difference in time between a feature of the plethysmograph waveform 210 and a feature of the ECG waveform 220. For example, in one embodiment, the PWTT can be obtained from the difference in time between the R-wave peak on the ECG waveform 220 and a foot point on the plethysmograph waveform 210. The foot point of the plethysmograph waveform 210 can correspond to the time of earliest onset of arrival of the pulse at a location away from the heart (e.g., at a patient's finger). In other embodiments, the PWTT can be obtained from the difference in time between either the Q-wave or the S-wave on the ECG waveform 220 and a feature on the plethysmograph waveform 210 (e.g., a foot point, peak, or some other feature).
Calculated in this manner from the plethysmograph and ECG waveforms 210, 220, PWTT can be fairly accurate for some patients. However, in some cases, using PWTT to measure changes in blood pressure provides inaccurate or unexpected results. At least a partial explanation of these unexpected results can be seen in
In
The PEP 216 can be defined in different ways. For instance, in certain embodiments, the PEP 216 includes the difference in time between ventricular contraction and cardiac ejection of blood into the aorta. The PEP 216 can also be considered as a measured interval from the onset of ventricular depolarization, such as a Q-wave (or other feature) of an ECG, to the beginning of mechanical contraction of the heart muscle. For example, the PEP 216 can represent the difference in time from the onset of the QRS complex of the ECG signal 220 to when cardiac ejection actually occurs. Further, the PEP 216 can also be considered as the time interval from the beginning of the electrical activation of the ventricles to the opening of the aortic valve.
The value of the PEP 216 can fluctuate based on patient condition, age, sex, and medications taken by the patient, among possibly other factors. In some patients, the PEP 216 can account for a significant portion of the PWTT 212, including even as much as about 50% of the PWTT 212. Because PEP 216 can account for a significant portion of overall PWTT 212, including the PEP 216 in a PWTT measurement can result in inaccurate determinations of changes in a patient's blood pressure. In certain circumstances, this can even lead to not detecting a clinically significant change in blood pressure and not initiating an occlusive cuff measurement for confirmation.
Thus, in certain embodiments, the arterial PWTT 214, which accounts for the PEP 216, can more accurately correlate with changes in a patient's blood pressure than the overall PWTT 212. Thus, it can be advantageous to detect changes in the arterial PWTT 214 and to use these changes to trigger occlusive cuff measurements. The arterial PWTT 214 can be determined in some embodiments by calculating the PEP 216 and subtracting the PEP 216 value from the overall PWTT 212.
The PEP 216 can be derived, at least in part, from another physiological signal. Such a physiological signal can be indicative of cardiac ejection. Example physiological signals can include, but are not limited to, bioimpedance signals and acoustic signals. For example, in one embodiment, the PEP 216 can be derived from a feature of the ECG waveform 220 and a feature of another physiological signal. As another example, in another embodiment, the PEP 216 can be derived from a feature of the plethysmograph waveform 210 and a feature of another physiological signal. As yet another example, the PEP 216 can be accounted for by deriving arterial PWTT directly from a feature of an acoustic heart sound waveform and an acoustic waveform on an extremity, such as the hand, wrist, or limb.
The first acoustic waveform 230 can include heart sounds of the patient corresponding to the closing of heart valves at the transition between ventricular systole and diastole. For example, the heart sounds can include first heart sounds (e.g., S1 heart sounds) 232 corresponding to the closure of the atrioventricular valves at the time ventricular systole begins and ventricular diastole ends and second heart sounds (e.g., S2 heart sounds) 234 corresponding to the closure of the aortic valve and the pulmonary valve at the time ventricular systole ends and ventricular diastole begins. The occurrence of the S1 heart sound can identify the start time of ejection of blood from the heart and the occurrence of the S2 heart sound can mark the end time or approximate end time of ejection of blood from the heart. Accordingly, the actual ejection of blood from the ventricles may occur for patients at the first heart sound (e.g., at the start, peak, or end of the first heart sound), between the start of the first heart sound (the S1 sound) and the start of the second heart sound (the S2 sound), or at the second heart sound (e.g., start, peak, or end of the second heart sound).
The second acoustic waveform 240 can include an arterial pulse at a second location remote from the heart (e.g., at a patient's wrist or neck). The second acoustic waveform 240 shown in
In some embodiments, the arterial PWTT can represent a difference in time between a feature of the first acoustic waveform (e.g., heart sounds waveform) and a feature of the second acoustic waveform (e.g., wrist pulse waveform). For example, in one embodiment, the arterial PWTT can be obtained from the difference in time between a feature of the first heart sound (the S1 sound) 232 on the acoustic heart sounds waveform 230 (e.g., start, maximum peak, end, some other feature of the S1 sound 242) and a feature of the acoustic wrist pulse waveform 240 (e.g., bottom onset or upstroke point 236 of the waveform 240 or start, maximum peak, end, some other feature of the waveform 240). In other embodiments, the arterial PWTT can be obtained from the difference in time between a determined centroid location of the S1 sound 232 or a location of the centroid of the energy from the start of the Si sound 232 until the start of the S2 sound 234 and a feature on the acoustic wrist pulse waveform (e.g., a bottom onset, a foot point, a peak, or some other feature). In some embodiments, the envelope of the waveform 230 or 240 is obtained and used in the analysis described herein, e.g., by finding a feature of the envelope rather than the waveform 230 or 240 itself.
In one embodiment, the arterial PWTT can be obtained from the difference in time from a location between the S1 and S2 heart sounds 232, 234 and/or between a centroid of the energy of the S1 and S2 sounds 232, 234 and the bottom onset of a corresponding pulse of an acoustic arterial pulse waveform (e.g., an acoustic wrist pulse waveform or an acoustic carotid pulse waveform). In some embodiments, an arterial PWTT determination based on identified features of two mechanical acoustic waveforms advantageously provides a more stable result than a PWTT determination based on an identified feature of an electrical waveform (e.g., ECG waveform) and an identified feature of a mechanical waveform (e.g., photoplethysmograph waveform).
Turning to
The acoustic carotid pulse waveform 250 can help to provide another measurement indicator (e.g., a control or reference or another input component) that can be used to determine the arterial pulse wave transit time or other arterial properties because the distance is known between the two sensors. The acoustic carotid pulse waveform 250 or any of the other waveforms can provide an indication of patient breathing, as shown by the presence of noise 255 on the acoustic carotid pulse waveform 250. In some implementations, the acoustic carotid pulse waveform 230 can be used in place of the wrist pulse waveform 240 to determine the arterial PWTT.
In some embodiments, the PEP is derived from one or more features of one or more acoustic signals. In one embodiment, the PEP is determined from the time of the start of the S1 heart sound 232 to the time of the end of the S1 heart sound 232. In other embodiments, the PEP can be derived from a feature of an ECG waveform 260 and a feature of another physiological signal (e.g., a pleth signal or an acoustic signal). One way to measure PEP is to determine the difference between an R wave peak of the ECG waveform 260 and a feature of the S1 sound 212 on the acoustic heart sounds waveform 230 (e.g., a foot point, peak, centroid, or other feature or derived location). More generally, PEP can be determined as a difference in time between any feature of the ECG waveform 260 and any feature of the acoustic heart sounds waveform 230, including in some embodiments, a feature of the S2 heart sound 234. The PEP can vary depending on patient pathology, and a determination of PEP can provide information regarding heart conditions to a clinician. In some embodiments, PEP is not calculated or used at all by the parameter calculation system 100 because the arterial PWTT is determined by the acoustic sensors.
In the depicted embodiment, the system 300 includes a parameter calculator 310, which can be implemented in hardware and/or software. The parameter calculator 310 is a more detailed implementation of the parameter calculator 110 of
The example parameter calculator 310 shown includes a blood pressure analyzer 312 and a noninvasive blood pressure module 314. The blood pressure analyzer 312 can calculate arterial PWTT using the outputs of some or all of the various sensors 302, 304, 306, and 308. Based at least in part on this calculated PWTT, the blood pressure analyzer 312 can send a trigger signal to the noninvasive blood pressure module 314. In response to receiving this trigger signal, the non-invasive blood pressure module 314 can cause the blood pressure cuff 320 to take a blood pressure measurement. In some embodiments, the non-invasive blood pressure module 314 is a separate component from the parameter calculator 310, for example, on an Original Equipment Manufacture (OEM) board or the like.
In one embodiment, the acoustic sensor 302 is placed over the heart or near the heart of a patient so as to detect heart sounds of the patient. The acoustic sensor 302 can be positioned on the chest, back, neck, side, abdomen, or other area of the body so as to detect the heart sounds. Heart sounds can include, among others, first and second heart sounds. The first heart sound can correspond to systole, or the contraction of the ventricles and corresponding ejection of blood from the heart. PEP can therefore be measured as a time difference between a feature of the ECG waveform derived from the electrical sensor(s) 304 and a first heart sound feature of an acoustic waveform derived from the acoustic sensor 302. The second heart sound can correspond to the beginning of diastole.
For example, referring to
Referring again to
For instance, referring to
Thus, in certain embodiments, the acoustic and/or bioimpedance sensors 302, 306 of
In other implementations, two acoustic sensors 302 of
The illustrated blood pressure monitoring system 500A is coupled to a patient 510. The patient 510 is shown with a cuff 522 attached to an upper arm. The cuff 522 can be implemented in combination with an automatic occlusive cuff control unit 520. The cuff 522 can be in communication with the automatic occlusive cuff control unit 520 via a cable 524. The control unit 520 can control the inflation of the cuff 522 and receive signals from the cuff 522 regarding systolic and diastolic blood pressure.
In addition to the automatic occlusive cuff, ECG sensors 562A and 562B can be coupled to the patient 510. The ECG sensors 562A, 562B can provide any of the ECG signals described above. The ECG sensors 562A and 562B can be implemented as dual electrodes or split electrodes. While the illustrated blood pressure monitoring system includes two ECG sensors 562A and 562B, in other embodiments, only one ECG sensor can be coupled to patient 510. In yet other embodiments, more than two ECG sensors can be coupled to the patient 510, such as three or more sensors. In addition, ECG sensors can be placed at different measurement site(s) than illustrated in
The illustrated ECG sensors 562A, 562B can be coupled to an ECG unit 560 via cables 564A and 564B, respectively. The ECG unit 560 can interface with the ECG sensors 562A, 562B and provide an ECG signal to the processor 530. In some embodiments, the ECG unit can convert and output of ECG sensors 562A, 562B from an analog signal to a digital signal and/or perform other pre-processing. The ECG unit 560 can be implemented separate from the processor 530 or alternatively as part of the processor 530.
An optical sensor 552 can also be coupled to the patient 510. The optical sensor 552 can provide any of the plethysmograph waveforms illustrated in
An acoustic sensor 572 can also be coupled to the patient 510. The acoustic sensor 552 can provide any of the acoustic signals and waveforms described above. The illustrated acoustic sensor 572 is coupled to the patient 510 at a measurement site near the patient's heart. In other embodiments, the acoustic sensor can be coupled to the patient 510 at different measurement sites, so long as the acoustic sensor can provide useful information indicative of cardiac ejection. In other embodiments, more than one acoustic sensor 572 can be used. More detail regarding the acoustic sensor 572 will be provided below in connection with
The acoustic module 570 can be coupled to the acoustic sensor 572 via cable 574. The acoustic module 570 can interface with the acoustic sensor 572 and provide an acoustic signal to the processor 530. In some embodiments, the acoustic module can convert and output of the acoustic sensor 572 from an analog signal to a digital signal and/or perform other pre-processing. The acoustic module 570 can be implemented separate from the processor 530 or alternatively as part of the processor 530.
The processor 530 can advantageously be used to measure indicators of blood pressure, such as PWTT, PEP, and/or arterial PWTT, using information provided by the ECG unit 560, the oximeter unit 550, and the acoustic module 570. The processor 530 can include, for example, one or more microprocessors, microcontrollers, cores, digital signal processors (DSPs), or the like. The processor 530 can store instructions in a computer-readable medium. The processor 530 can also perform other operations for the blood pressure monitoring system 500A that are not explicitly described herein.
The processor 530 can also be coupled to the automatic occlusive cuff control unit 520 via line 532. The processor 530 can receive information regarding a blood pressure measurement of the patient 510 from the automatic occlusive cuff control unit 520, and can activate the automatic occlusive cuff control unit 520 via the line 532.
In certain embodiments, the processor 530 determines the arterial PWTT, compensated for PEP, using the acoustic sensor 572, the ECG sensors 562A, and the optical sensor 552. The processor 530 can track changes in this arterial PWTT and trigger the automatic occlusive cuff control unit 520 to take a blood pressure measurement with the cuff 522. The PEP-compensated arterial PWTT calculations can be more accurate than currently-available PWTT calculations that do not take PEP into account. Thus, in certain embodiments, the blood pressure monitoring system 500A can more effectively monitor the patient's 510 blood pressure with potentially greater comfort for the patient 510.
The bioimpedance sensors 582A, 582B, 582C, 582D can be coupled to the patient 510 at various measurement sites. For example, as illustrated, two bioimpedance sensors 582A and 582B can be coupled to the sides of the patient 510 and two bioimpedance sensors 582C and 582D can be coupled to the neck of the patient 510. Other suitable measurement sites can be used in other embodiments. The bioimpedance sensors 582A, 582B, 582C, 582D can be used to provide the bioimpedance waveforms described above with respect to
The bioimpedance unit 580 can be coupled to one or more of the bioimpedance sensors 582A, 582B, 582C, 582D via one or more cables 584A, 584B, 584C, 584D, respectively. The bioimpedance unit 580 can interface with one or more of the bioimpedance sensors 582A, 582B, 582C, 582D and provide one or more bioimpedance signals to the processor 530. In some embodiments, the bioimpedance unit 580 can convert an output of one or more of the bioimpedance sensors 582A, 582B, 582C, 582D from an analog signal to a digital signal and/or perform other pre-processing. The bioimpedance unit 580 can be implemented separate from the processor 530 or alternatively as part of the processor 530.
In certain embodiments, the processor 530 determines the arterial PWTT, compensated for PEP, using the bioimpedance sensors 582, the ECG sensors 562A, 562B and the optical sensor 552. The processor 530 can track changes in this arterial PWTT and trigger the automatic occlusive cuff control unit 520 to take a blood pressure measurement with the cuff 522. The PEP-compensated arterial PWTT calculations can be more accurate than currently-available PWTT calculations that do not take PEP into account. Thus, in certain embodiments, the blood pressure monitoring system 500B can more effectively monitor the patient's 510 blood pressure with potentially greater comfort for the patient 510.
Although shown separately for ease of illustration, in certain embodiments the ECG sensors 562A, 562B and the bioimpedance sensors 582 can be combined. For instance, the bioimpedance sensors 582 can obtain ECG data in some implementations, and vice versa.
With continued reference to
The blood pressure cuff 710 can be attached to an upper arm. The cuff 710 can be implemented in combination with an automatic occlusive cuff control unit (not shown). The cuff 710 can be in communication with the automatic occlusive cuff control unit via a cable and/or hose. The control unit can control the inflation of the cuff 710 and receive signals from the cuff 710 regarding systolic and diastolic blood pressure.
The acoustic sensors 702A-702C can be coupled to an acoustic module (not shown) via one or more cables or wirelessly. The acoustic module can interface with the acoustic sensors 702A-702C and provide acoustic signals to the processor 330. In some embodiments, the acoustic module can convert an output of the acoustic sensors 702A-702C from an analog signal to a digital signal and/or perform other pre-processing. The acoustic module can be implemented separate from the processor 330 or alternatively as part of the processor 330 or even as part of one or more of the sensors 702A-702C.
The ECG sensors 704A-704C can provide any of the ECG signals described herein. The ECG sensors 704A-704C can be implemented as dual electrodes or split electrodes. While the patient 700 in
The illustrated ECG sensors 704A-704C can be coupled to an ECG unit (not shown) via cables or wirelessly. The ECG unit can interface with the ECG sensors 704A-704C and provide an ECG signal to a processor 330. In some embodiments, the ECG unit can convert an output of ECG sensors 704A-704C from an analog signal to a digital signal and/or perform other pre-processing. The ECG unit can be implemented separate from the processor 330 or alternatively as part of the processor 330.
The bioimpedance sensors 706A-706D can be coupled to the patient 700 at various measurement sites. For example, as illustrated, two bioimpedance sensors 706A and 706B can be coupled to the sides of the patient 700 and two bioimpedance sensors 706C and 706D can be coupled to the neck of the patient 700. Other suitable measurement sites can be used in other embodiments. The bioimpedance sensors 706A-706D can be used to provide bioimpedance waveforms that can be used in determining measurements indicative of blood pressure (e.g., overall PWTT, PEP, arterial PWTT). Suitable bioimpedance sensors 706A-706D can include electrodes or the like.
The bioimpedance sensors 706A-706D can be coupled to a bioimpedance unit (not shown). The bioimpedance unit can interface with one or more of the bioimpedance sensors 706A-706D and provide one or more bioimpedance signals to the processor 330. In some embodiments, the bioimpedance unit can convert an output of one or more of the bioimpedance sensors 706A-706D from an analog signal to a digital signal and/or perform other pre-processing. The bioimpedance unit can be implemented separate from the processor 330 or alternatively as part of the processor 330.
Although shown separately for ease of illustration, in certain embodiments the ECG sensors 704A-704C and the bioimpedance sensors 706A-706D can be combined. For instance, the bioimpedance sensors 706A-706D can obtain ECG data in some implementations, and vice versa.
An optical sensor 708 can also be coupled to the patient 700 (e.g., to a patient's finger). The illustrated optical sensor 708 can be coupled to an oximeter unit (not shown) via a cable or wirelessly. The oximeter unit can interface with the optical sensor 708 and provide an optical signal to a processor 330. In some embodiments, the oximeter unit can convert an output of optical sensor 708 from an analog signal to a digital signal and/or perform other pre-processing. The oximeter unit can be implemented separate from the processor 330 or alternatively as part of the processor 330. It should be noted that in certain embodiments, the optical sensor 708 can provide data to a monitor other than a pulse oximeter.
The processor 330 of
The processor 330 can also be coupled to the automatic occlusive cuff control unit. The processor 330 can receive information regarding a blood pressure measurement of the patient 700 from the automatic occlusive cuff control unit, and can activate the automatic occlusive cuff control unit.
In certain embodiments, the processor 330 determines the arterial PWTT, using two of the acoustic sensors 702A-702C, independently or in conjunction with an additional acoustic sensor, one or more of the ECG sensors 704A-704C, one or more bioimpedance sensors 706A-706D, and the optical sensor 708. In some embodiments, the processor 330 determines the arterial PWTT using a combination of one or more acoustic sensors and one or more non-acoustic sensors (for example, using two bioimpedance sensors and one acoustic sensor). The processor 330 can track changes in this arterial PWTT and trigger the automatic occlusive cuff control unit to take a blood pressure measurement with the cuff 710. The arterial PWTT calculations obtained can be more accurate than currently-available PWTT calculations that do not take PEP into account or require subtraction of the PEP to determine the arterial PWTT.
In an embodiment, the sensor assembly 801 can include a sensing element, such as, for example, a piezoelectric device or other acoustic sensing device. The sensing element can generate a voltage that is responsive to vibrations generated by the patient, and the sensor can include circuitry to transmit the voltage generated by the sensing element to a processor for processing. In an embodiment, the acoustic sensor assembly 801 can include circuitry for detecting and transmitting information related to biological sounds to a physiological monitor. These biological sounds may include heart, breathing, and/or digestive system sounds, in addition to many other physiological phenomena. The acoustic sensor 815 in certain embodiments can be a biological sound sensor, such as the sensors described herein. In some embodiments, the biological sound sensor is one of the sensors such as those described in the U.S. patent application Ser. No. 12/044,883, filed Mar. 7, 2008, entitled “Systems and Methods for Determining a Physiological Condition Using an Acoustic Monitor,” which is incorporated in its entirety by reference herein. In other embodiments, the acoustic sensor 815 can include a biological sound sensor such as those described in U.S. Pat. No. 8,661,161, which is incorporated by reference herein. Other embodiments include other suitable acoustic sensors.
The attachment sub-assembly 804 can include a first elongate portion 806 and a second elongate portion 808. The first elongate portion 806 and the second elongate portion 808 can include patient adhesive (e.g., in some embodiments, tape, glue, a suction device, etc.) attached to an elongate member 810. The adhesive on the elongate portions 806, 508 can be used to secure the sensor subassembly 802 to a patient's skin. The elongate member 810 can beneficially bias the sensor subassembly 802 in tension against the patient's skin and reduce stress on the connection between the patient adhesive and the skin. A removable backing can be provided with the patient adhesive to protect the adhesive surface prior to affixing to a patient's skin.
The sensor cable 807 can be electrically coupled to the sensor subassembly 802 via a printed circuit board (“PCB”) (not shown) in the sensor subassembly 802. Through this contact, signals can be communicated from the sensor subassembly to the physiological monitor via the sensor cable 807 and the cable 811.
In various embodiments, not all of the components illustrated in
Referring specifically to
As described above, this initial PWTT can include the arterial PWTT as well as the PEP. Thus, to obtain the arterial PWTT, further blocks of the process 900A can determine PEP so as to compensate the initial PWTT for the PEP. At block 904, a first heart sound is detected from the acoustic waveform. The PEP is then calculated at block 906 by determining a time difference between a feature of the ECG waveform and a feature of the first heart sound. The feature used on the ECG waveform to calculate the PEP 906 can be the same feature used to calculate the initial PWTT at block 902. Alternatively, different ECG features can be used to calculate PEP and the initial PWTT. At block 908, the PEP is subtracted from the initial PWTT to produce an arterial PWTT value. This arterial PWTT value can be used in determining if an automatic occlusive cuff should take a blood pressure measurement from a patient (see
Advantageously, in certain embodiments, the process 900A can be performed continuously or substantially continuously so as to monitor a patient's arterial PWTT over time. The process 900A can therefore dynamically determine a patient's changing PEP over time and can compensate initial PWTT values according to this changing PEP. The process 900A can therefore, in certain embodiments, calculate more accurate PWTT than currently-available devices.
It should further be noted that the process 900A shown can also be more accurate than processes that calculate the arterial PWTT without using an ECG waveform. Because of its prominent R-wave peak, the ECG waveform can be a more reliable triggering point than cardiac ejection signals such as heart sounds or bioimpedance signals. Accordingly, the ECG signal can be used to identify relevant cardiac ejection signal. For example, the subsequent cardiac ejection signal after an ECG signal may be the next cardiac ejection signal of interest.
Another advantage of using the ECG as a triggering signal for calculating PWTT is related to the occasional ambiguity of the cardiac ejection signal. In some cases, it may be difficult or impossible to distinguish a cardiac ejection signal from noise. In such cases, the parameter calculator 110 or 310 can use the previous PEP value as the current PEP value and calculate arterial PWTT as the difference between the ECG-to-arterial pulse signal and the previous PEP value. As PEP values may change infrequently, this substitution may be accurate.
Further, because the occurrence and/or location of the cardiac ejection signal can be ambiguous, it can be beneficial to more aggressively average the PEP measurements over time to compensate for this ambiguity. For example, a relatively slower averaging filter, which may include a longer time window of data points, may be applied to the PEP values. In contrast, the overall PWTT values may change more rapidly (see, e.g.,
Like the process 900A, the process 900B receives a plethysmograph waveform and an ECG waveform. At block 912, an initial PWTT is calculated from these waveforms in the manner described above with respect to
Like the process 900A, the process 900B can be performed continuously or substantially continuously so as to monitor a patient's arterial PWTT over time. The process 900B can therefore dynamically determine a patient's changing PEP over time and can compensate initial PWTT values according to this changing PEP. The process 900B can therefore, in certain embodiments, calculate more accurate PWTT than currently-available devices.
The process 900C receives a plethysmograph and acoustic waveform, or a plethysmograph and bioimpedance waveform. At block 922, a feature of the plethysmograph waveform is identified. At block 924, a feature of the acoustic or bioimpedance waveform is identified. Cardiac ejection can precede the arrival of the resulting pulse at an extremity. Thus, a feature from the plethysmograph waveform obtained at the extremity can be identified when it occurs at a later time than the identified feature from the acoustic or bioimpedance waveform.
At block 926, a time difference between the identified waveform features is determined. This time is the arterial PWTT. This arterial PWTT value can be used in determining if an automatic occlusive cuff should take a blood pressure measurement from a patient (see
Like the processes 900A and 900B, the process 900C can be performed continuously or substantially continuously so as to monitor a patient's arterial PWTT over time. The process 900C can therefore dynamically determine a patient's changing PEP over time and can compensate initial PWTT values according to this changing PEP. The process 900C can therefore, in certain embodiments, calculate more accurate PWTT than currently-available devices.
The process 900C can be modified in one embodiment to receive an ECG signal input to assist with identifying the feature of the plethysmograph waveform at block 922. It can be difficult to properly identify features from the plethysmograph waveform due to the double-peak nature of the waveform, as well as due to noise. An ECG signal, on the other hand, can have clearly-identifiable landmarks, including the R wave peak, among others. An ECG signal can therefore be used as a gating function to determine which feature of the plethysmograph waveform should be considered and/or which feature of the acoustic or bioimpedance waveform should be considered. In one embodiment, the first peak, foot point, or other feature in the plethysmograph occurring after a feature identified from the ECG signal can be identified as the relevant plethysmograph feature. Similarly, the first foot peak, or other feature of the acoustic or bioimpedance waveform occurring after a feature identified from the ECG signal can be identified as the relevant cardiac ejection signal feature. The ECG signal can therefore resolve ambiguities in the plethysmograph waveform, thereby improving noise immunity and/or noise reduction. Similarly, the ECG signal can also be used as a reliable identifier of a cardiac ejection signal, thereby improving the accuracy of the arterial PWTT calculation.
With reference to
The process 900D receives an acoustic heart sounds waveform and an acoustic pulse waveform. The acoustic pulse waveform can be, for example, an acoustic wrist pulse waveform or an acoustic carotid pulse waveform, as described above; however, the acoustic pulse waveform can be received from an acoustic sensor positioned at other locations as well. At block 927, a feature of the acoustic heart sounds waveform is identified. At block 928, a feature of the acoustic pulse waveform is identified. The feature of the acoustic heart sounds waveform can correspond to the time of cardiac ejection, which precedes the time of arrival of the resulting pulse at a location of the acoustic sensor from which the acoustic pulse waveform is generated.
Features on these waveforms can be determined using signal processing techniques including, but not limited to, taking derivatives of the waveforms, detecting peaks and troughs of the waveform, comparing the waveforms to models and/or thresholds, determining the centroid of a feature of the waveform, taking an envelope of a portion of the waveform and identifying a feature of the envelope, combinations of the same, and the like. For example, a foot point on an acoustic waveform can be identified by the point at which the derivative of the acoustic waveform is zero in a time window defined after an electrical trigger (e.g., as identified by an ECG sensor). As another example, a centroid or “middle” of a pulse, burst or wave of an acoustic waveform can be determined. In some embodiments, the centroid can be determined by constructing an amplitude envelope of the pulse, sound burst, or pressure wave and then performing a normalized weighting of each time point according to the envelope amplitude, with the highest energy point of the envelope being the centroid time of the pulse or sound (e.g., heart sound). The centroid determination can be performed in the time domain or frequency domain. In some embodiments, the centroid determination includes sampling and/or filtering of the pulse, sound burst, or pressure wave. Such signal processing can be performed dynamically, in real time. Alternatively or additionally, such signal processing can be performed during post processing of data.
At block 929, a time difference between the identified waveform features is determined. This time can be considered to be the arterial PWTT in one embodiment. This arterial PWTT value can be used in determining if an automatic occlusive cuff should take a blood pressure measurement from a patient (see
The process 900D can be modified in one embodiment to receive an ECG signal input to assist with identifying the feature of the acoustic heart sounds waveform at block 927. It can be difficult to properly identify features from acoustic waveforms due to noise or other characteristics. An ECG signal, on the other hand, can have clearly-identifiable landmarks, including the R wave peak, among others. An ECG signal can therefore be used as a gating function to determine which heart sound should be considered. In one embodiment, the first heart sound of the acoustic heart sounds waveform occurring after a feature identified from the ECG signal can be identified as the relevant acoustic heart sounds feature. The ECG signal can therefore resolve ambiguities in the acoustic waveforms, thereby improving noise immunity and/or noise reduction. In some embodiments, the ECG signal can be used to identify the transition from electrical to mechanical behavior. The time delay between the ECG signal and the first heart sound (e.g., S1 sound) detected by the acoustic heart sounds sensor can provide an indication of the health of the heart or other potential pathological conditions that may warrant medical attention. However, the ECG signal input is not used or needed in other embodiments.
Referring specifically to
In some implementations, the initial arterial PWTT values (a-PWTT A and a-PWTT B) can be provided to a comparison module 936. The comparison module 906 can analyze the two initial arterial PWTT values to generate a final arterial PWTT output value. In some implementations, the comparison module 936 can compare the two initial arterial PWTT values to determine a difference between the two values. The comparison module 936 can derive a confidence value from the calculated difference. In other implementations, the comparison module 936 can average or otherwise combine the two initial arterial PWTT values to output a refined final arterial PWTT output value. In some embodiments, the two initial arterial PWTT values are weighted. In yet other implementations, the comparison module 936 can select one of the two initial arterial PWTT values to output as the final arterial PWTT output value. The comparison module 936 can make this selection based on confidence values, based on comparison to historical data or thresholds, based on patient-specific factors, and/or the like.
In some embodiments, the second pulse acoustic waveform can simply be used to provide another reference or gating point in identifying a feature of the first pulse acoustic waveform. In other embodiments, the second pulse acoustic waveform can be used to identify other patient characteristics (e.g., patient breaths, respiratory rate, respiratory pause, or other respiratory conditions, as discussed above).
Like the process 900E, the process 900E can calculate two arterial PWTT values (a-PWTT A and a-PWTT B) at PWTT determination blocks 932 and 934, respectively. The process 900C can also receive an ECG signal input, a plethysmograph signal input, and/or a bioimpedance signal input in addition to the acoustic signal inputs. An overall PWTT value (including arterial PWTT and PEP components) can be calculated at PWTT determination block 937 by determining a time difference between a feature of a plethysmograph waveform and a feature of an ECG waveform. Further blocks of the process 900C can determine PEP so as to compensate the overall PWTT for the PEP. The PEP is calculated at block 938 by determining a time difference between a feature of the ECG waveform and a feature of the acoustic heart sounds waveform or a bioimpedance waveform in the manner described above. The feature used on the ECG waveform to calculate the PEP 938 can be the same feature used to calculate the overall PWTT at block 936. Alternatively, different ECG features can be used to calculate PEP and the overall PWTT. At block 940, the PEP is subtracted from the initial PWTT to produce a third arterial PWTT value (a-PWTT C).
In other embodiments, the third arterial PWTT value can be derived from a time difference between a feature of an acoustic waveform or a bioimpedance waveform and a pleth waveform such that PEP need not be calculated, as described above.
Similar to the process 900E, the three arterial PWTT values can be received by the comparison module 936 and analyzed to output a final arterial PWTT value. In some implementations, the comparison module 936 can compare the three initial arterial PWTT values to determine differences between any two of the three values. The comparison module 936 can derive a confidence value from the calculated differences. In other implementations, the comparison module 936 can average or otherwise combine the three initial arterial PWTT values to output a refined final arterial PWTT output value. In some embodiments, the three initial arterial PWTT values are weighted. In yet other implementations, the comparison module 936 can select one of the three initial arterial PWTT values to output as the final arterial PWTT output value. The comparison module 936 can make this selection based on confidence values, based on comparison to historical data or thresholds, based on patient-specific factors, and/or the like.
In other embodiments, arterial PWTT values can be calculated using one or more non-acoustic sensors in combination with one or more acoustic sensors. For example, arterial PWTT values can be calculated from time differences between a feature of a bioimpedance waveform (e.g., generated from signals received from two bioimpedance sensors) and a feature of an acoustic waveform (e.g., received from an acoustic pulse sensor positioned over or proximate a wrist, leg or carotid artery).
At block 1002, a first arterial PWTT measurement is determined at a first point in time. The arterial PWTT can be determined using any of the techniques above, such as by calculating PEP and by compensating an overall PWTT value with the PEP. Similarly, a second arterial PWTT measurement is taken at a second point in time at block 1004. These arterial PWTT measurements can be taken from successive heart beats in one embodiment. In another embodiment, the first and second arterial PWTT values each represent arterial PWTT values averaged over multiple heartbeats.
At block 1006, a difference between the two arterial PWTT measurements is determined. It is then determined at decision block 1008 whether a new blood pressure measurement is required. In certain embodiments, this decision can be made by determining whether the difference between the two measurements is greater than a threshold. A difference greater than a threshold can be indicative of a change in a patient's blood pressure. Therefore, if the difference is greater than the threshold, an occlusive cuff is triggered to take a new blood pressure measurement at block 1010. If the difference is not greater than the threshold, then the process 1000 loops back to block 1002. Effectively, the process 1000 therefore can trigger occlusive cuff measurements when the threshold is exceeded and can continue monitoring arterial PWTT measurements otherwise.
In certain embodiments, the process 1000 analyzes changes in arterial PWTT measurements using an absolute difference technique or a moving difference technique. With the absolute difference technique, the process 1000 measures the PWTT at a first fixed time. Subsequent arterial PWTT measurements (e.g., the second measurement at block 1004) are compared to the initial arterial PWTT at the first fixed time to determine whether the difference between these measurements exceeds a threshold. With the moving difference technique, the first and second arterial PWTT measurements are compared for successive points in time. The first arterial PWTT measurement is therefore not taken at a fixed time but instead changes over time. Thus, the moving difference technique can approximate a derivative of the arterial PWTT measurements. The moving difference can be compared to a threshold at block 1008. An advantage of using the moving difference technique is that it can potentially ignore drifts in arterial PWTT measurements due to calibration changes or other errors.
Thus, in certain embodiments, the process 1000 can refrain from triggering an occlusive cuff until the non-invasive measurement differs enough to trigger such a measurement. Advantageously, in certain embodiments, the process 1000 can therefore allow a user to postpone the discomfort and potential physiological damage associated with occlusive blood pressure measurements, while the non-invasive measurement (e.g., arterial PWTT) is within a certain tolerance.
Although the PWTT measurements have been described herein as being used to trigger an occlusive cuff, in certain embodiments the PWTT measurements can also or instead be used to derive an estimate of blood pressure. A calibration function or curve can be determined that maps PWTT measurements to blood pressure values. The slope and intercept of the calibration curve can be determined experimentally.
PWTT Noise Compensation
As described above, in addition to compensating PWTT for PEP, the parameter calculation system 100 can also compensate PWTT data for noise.
One technique to reduce the effects of noise in the PWTT data is to average the PWTT data overtime. A time-averaged PWTT waveform 1120 is shown in
In certain embodiments, averaging can be improved by dynamically adjusting the averaging time according to the amount of noise present in the PWTT data. If a higher level of noise is present, a longer averaging time can be selected. Conversely, if less noise is present, a shorter averaging time can be used. However, it can be difficult to differentiate noise from signal in the PWTT data. Thus, determining the level of the noise in the PWTT data and therefore the amount of averaging to perform can be nontrivial.
To select an appropriate averaging time, in one embodiment a signal correlated with the PWTT data can be analyzed. Heart rate is such a correlated signal, and respiratory rate is another. An example heart rate signal is shown plotted over time as a waveform 1130 in
Another possible use of the heart rate (or respiratory rate) data is to use the heart rate (or respiratory rate) as a noise reference in an adaptive filter. For example, the system 100 (or any other system described herein) can adaptively filter or adaptively cancel noise in the PWTT data using the heart rate as a noise reference. Any of a variety of adaptive algorithms can be used by the parameter calculation system 100. For instance, the adaptive algorithm can implement one or more of the following: a least mean squares algorithm (LMS), a least squares algorithm, a recursive least squares (RLS) algorithm, a Kalman filter, a joint process estimator, an adaptive joint process estimator, a least-squares lattice joint process estimator, a least-squares lattice predictor, a correlation canceller, optimized or frequency domain implementations of any of the above, any other linear predictor, combinations of the same, and the like. In still other embodiments, the PWTT data can be both adaptively filtered and averaged using a dynamically-adjusted averaging filter.
Further, as can be seen in
At block 1202, statistics of the heart rate data are analyzed to determine a measure of the noise in the heart rate data. A variety of statistics of the heart rate data can be calculated at block 1202, including variance, standard deviation, and entropy, combinations of the same, and the like. For example, the standard deviation can be calculated from the heart rate data to measure the degree of dispersion or variability in the heart rate data. A higher standard deviation can reflect greater variability in the heart rate data, which can in turn reflect more noise in the heart rate data. Conversely, a lower standard deviation can reflect lower noise in the heart rate data. More generally, any measure of variation or change in the heart rate data can be calculated at block 1202.
At block 1204, one or more averaging parameters of an averaging filter can be adjusted based on the statistical calculation. In one embodiment, an averaging parameter such as averaging time is adjusted. For example, if the standard deviation of the heart rate data is relatively high, reflecting more noise, a relatively long averaging time can be selected. On the other hand, if the standard deviation is relatively lower, reflecting less noise, a relatively shorter averaging time can be selected. More generally, the one or more averaging parameters can include any parameter of the averaging filter that can be tuned. The averaging parameters can therefore include the order of the averaging filter, the number of points averaged (e.g., for a simple moving average filter), the time constant of the filter (e.g., for a low pass averaging filter), and an array of coefficients for more complex averaging filters (such as any of the adaptive filters described above with respect to
At block 1210, the averaging filter with the selected averaging time is applied to the PWTT data. Averaging can include computing a mean, median, and/or mode. In some embodiments, a weighted average of PWTT measurements can be applied. For example, the averaging filter can place a greater weight on more recent PWTT data and/or data with a corresponding statistic that indicates lower variability. For signals with relatively lower variability in the heart rate data, the averaging filter may not be applied to the PWTT input at all. Further, in other embodiments, the statistics of the PWTT signal can be evaluated to determine the amount of noise and therefore averaging time, rather than evaluating the statistics of the heart rate signal.
Phase Impact Reduction
In some embodiments, the PWTT measurements and calculations described herein are determined in terms of time. Accordingly, phase delay or phase noise can be introduced between successive filters of the parameter calculation system or blood pressure monitoring system.
The pre-amplification module 1305 can receive and amplify the voltage signal from the acoustic sensors, such as by a predetermined gain. In some implementations, the pre-amplification module 1305 introduces a high input impedance to drop the high pass filtering effect of the piezoelectric acoustic sensors. In some implementations, the pre-amplification module 1305 includes circuitry to convert an AC signal output from the acoustic sensor to a DC signal. In some implementations, the one or more filters 1310 include one or more low pass filters to allow the low frequency heart and pulse acoustic signals detected by the acoustic sensors while attenuating high frequency signals, such as high frequency noise. The one or more filters 1310 may include other types of filters, such as high pass or bandpass filters, instead of or in addition to, the one or more low pass filters. In some implementations, the one or more filters 1310 can be adjusted to reduce the phase distortion by changing the location of the zeros and/or poles of the one or more filters 1310.
In some implementations, the cutoff frequency of the acoustic sensors (which can be represented as capacitors in terms of frequency response analysis) can effectively be changed to a much lower frequency than an acoustic sensor used for respiration detection (e.g., to 0.01 Hz or 0.1 Hz). According to some embodiments, the acoustic sensors can have a cutoff frequency that is inversely dependent on the capacitance of the sensor and the input resistance of the amplifier or other circuit that receives the signal. The acoustic sensors may be modified to achieve a much lower cutoff frequency. For example, the low frequency response can be extended by changing the piezoelectric characteristics of the acoustic sensor (e.g., making the capacitance of the piezoelectric material itself larger, such as by the composition, size, thickness, etc. of the piezoelectric material), by making the input resistance higher, and/or by placing a large (as compared to the piezoelectric capacitance) capacitor in shunt with the acoustic sensor. In some embodiments, rather than lowering the cutoff frequency of the acoustic sensor itself, a compensatory filter can be inserted in the signal path. In one embodiment, the cutoff frequency is allowed to be significantly higher than the frequency band of interest, such that the acoustic sensor is effectively responsive to the derivative of the signal. Thus, the compensatory filter can be an integrator, which recreates the original acoustic signal. In some embodiments, it may be neither necessary nor desirable to extend the low frequency response of the acoustic sensors. The output from the filters 1310 can be amplified into a higher voltage signal and then converted to a digital signal by the ADC converter 1315. In some embodiments, using a single ADC converter 1315 to convert each signal, or multiple of the signals, including acoustic, electrical, and/or optical, can also reduce phase distortion between the signals. Further, oversampling in the ADC 1315 can also reduce phase distortion between the signals. The digital signal can then pass to a digital signal processor for processing in preparation for display on a monitor or screen.
Patient Calibration
The individualized patient calibration process 1400 can reduce the effect of slope variability between patients by uniquely and individually calibrating the PWTT measurements for the individual patient, thereby reducing the inaccuracy of blood pressure measurement frequency or false alarms based on PWTT measurements. The individualized patient calibration process 1400 therefore advantageously provides a mechanism for more efficient interpretation of PWTT measurements for individual patients by compensating for the variability of slope. Alternatively, in one embodiment, a patient monitor (such as any of those described herein) can calculate a baseline PWTT variability offset that is applied to the calculation of PWTT for multiple patients. This baseline adjustment may, but need not, be calibrated to individual patients or segments of patients (e.g., segments for drug users, segments based on gender, age, or comorbidity).
The term PWTT measurements as used herein with respect to
The calibration process 1400 begins at block 1402, wherein at least two blood pressure measurements of a patient are obtained at different times. The blood pressure measurements can include just systolic blood pressure measurements, just diastolic blood pressure measurements, and/or combinations of the systolic and diastolic blood pressure measurements (for example, mean or median blood pressure measurements).
In some implementations, blood pressure measurements can be taken at two different elevations of known hydrostatic pressure at two different times. For example, a first blood pressure measurement can be taken when the patient is lying down on a bed or table with the arm at the patient's side and a second blood pressure measurement can be taken with the arm raised up at least approximately perpendicularly to the patient's body. The blood pressure measurements can be normalized to account for changes in pressure due to the change in elevation. The changes in pressure due to the change in elevation can be determined based on a measured or known distance between the locations of the measurements and calculated or known hydrostatic pressure and/or based on actual hydrostatic pressure measurements. The distance and/or pressure measurements can be obtained by any of a variety of sensors or transducers. In some embodiments, a wrist cuff is used to obtain the blood pressure measurements (which, in some embodiments, reduces the effects of the arterial-to-capillary time delays addressed above). Other methods can be used to obtain blood pressure measurements over time in accordance with yet other implementations.
At block 1404, pulse wave transit times are measured to correspond with the blood pressure measurements. Although block 1404 is illustrated as occurring after block 1402, the pulse wave transit times can be measured simultaneously or substantially simultaneously (e.g., within a few seconds or within a few milliseconds) with the blood pressure measurements. Accordingly, the pulse wave transit times can be mapped to their corresponding blood pressure measurements. The blood pressure measurements and pulse wave transit time measurements can be stored in memory (at least temporarily). In some embodiments, the memory can include a predetermined capacity of measurements and the oldest measurements can be replaced by new measurements when capacity has been reached. The stored measurements can be used to generate a calibration curve defined by a plot of the pulse wave transit times on one axis (e.g., vertical axis) and the corresponding blood pressure measurements on the other axis (e.g., horizontal axis).
At block 1406, an individual patient's slope corresponding to the change in pulse wave transit time per change in blood pressure (e.g., slope of the calibration curve) is determined from the blood pressure and PWTT measurements obtained at block 1402 and block 1404. A patient's PWTT ms/mmHg slope can be determined from two or more blood pressure measurements and two or more corresponding PWTT measurements. In accordance with some embodiments, the slope is inferred over time from a plurality of frequent blood pressure and corresponding PWTT measurements. The slope determination can then be refined over time through less frequent natural blood pressure and corresponding PWTT measurements.
Based on the determined slope of the patient, a personalized, or individualized, patient calibration factor can be identified at block 1408 and used to interpret subsequent pulse wave transit time measurements of the patient with reduced concern for patient variability.
At block 1410, a pulse wave transit time is measured (for example, an arterial pulse wave transit time can be measured as described herein). At block 1412, the process 1400 estimates a change in the patient's blood pressure based on the measured pulse wave transit time. The measured pulse wave transit time has been calibrated using the individualized patient calibration factor, thereby reducing patient variability.
At decision block 1414, the process 1400 determines whether the estimated blood pressure change satisfies a condition that warrants performance of an action (e.g., whether the estimated blood pressure change is significant enough to perform an action). The condition can be, for example, a blood pressure change that exceeds a threshold blood pressure change value, cuff triggering value, a patient alarm triggering value, and/or the like. The condition can be patient-specific based on patient-specific factors or generic to all patients. If the condition is satisfied, the process 1400 proceeds to block 1416, wherein an appropriate action is performed based on the satisfied condition. For example, if an estimated blood pressure change exceeds a threshold change, a blood pressure cuff measurement can be triggered to determine and/or confirm the accuracy of the estimated blood pressure change. In some embodiments, the new blood pressure measurement can be added to a running tally to refine the individualized patient calibration factor.
As another example, if an estimated blood pressure change exceeds an alarm condition, a patient alarm can be triggered so that the patient can receive immediate medical attention. In some embodiments, the alarm is triggered only if confidence in the estimated blood pressure change is above a predetermined level. In some embodiments, a blood pressure measurement is obtained to confirm the accuracy of the estimated blood pressure change prior to triggering an alarm.
In some implementations, the determination of whether the blood pressure change is significant enough to warrant an action at block 1408 includes a multivariate determination based on other factors in addition to pulse wave transit time (e.g., heart rate). For example, if heart rate and pulse wave transit time are changing, it is more likely that the blood pressure is changing in a manner such that an action is recommended to be performed.
In some situations, the patient's calibration curve slope can change due to changes in patient conditions (e.g., changes in hemodynamic state, introduction of drugs, etc.). Accordingly, in some implementations, the slope is tracked over time to determine whether a recalibration process may be recommended. Other inputs or physiological parameters, such as heart rate, can be analyzed in determining whether recalibration of the personalized patient calibration factor should be performed as well.
In other implementations, a slope of a patient's blood pressure over time can be determined instead of, or in addition to, the PWTT/blood pressure calibration curve slope and used to identify a personalized patient calibration factor, which can in turn be used to interpret pulse wave transit time measurements.
Terminology
Many other variations than those described herein will be apparent from this disclosure. For example, depending on the embodiment, certain acts, events, or functions of any of the algorithms described herein can be performed in a different sequence, can be added, merged, or left out all together (e.g., not all described acts or events are necessary for the practice of the algorithms). Moreover, in certain embodiments, acts or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially. In addition, different tasks or processes can be performed by different machines and/or computing systems that can function together.
The various illustrative logical blocks, modules, and algorithm steps described in connection with the embodiments disclosed herein can be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. For example, the parameter calculation system 100 can be implemented by one or more computer systems or by a computer system including one or more processors. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.
The various illustrative logical blocks and modules described in connection with the embodiments disclosed herein can be implemented or performed by a machine, such as a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general purpose processor can be a microprocessor, but in the alternative, the processor can be a controller, microcontroller, or state machine, combinations of the same, or the like. A processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration. A computing environment can include any type of computer system, including, but not limited to, a computer system based on a microprocessor, a mainframe computer, a digital signal processor, a portable computing device, a personal organizer, a device controller, and a computational engine within an appliance, to name a few.
The steps of a method, process, or algorithm described in connection with the embodiments disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM, or any other form of non-transitory computer-readable storage medium, media, or physical computer storage known in the art. An exemplary storage medium can be coupled to the processor such that the processor can read information from, and/or write information to, the storage medium. The storage medium can be external to or remote from the processor. For example, the storage medium may be a storage device accessible by the processor over a network. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.
Conditional language used herein, such as, among others, “can,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or states. Thus, such conditional language is not generally intended to imply that features, elements and/or states are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or states are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.
While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As will be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others.
This application is a continuation of U.S. patent application Ser. No. 13/189,396, filed Jul. 22, 2011, entitled “Non-Invasive Blood Pressure Measurement System,” which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 61/366,862, filed Jul. 22, 2010, entitled “System for Triggering a Non-Invasive Blood Pressure Device” and to U.S. Provisional Application No. 61/469,511, filed Mar. 30, 2011, entitled “Non-Invasive Blood Pressure Measurement System,” the disclosures of which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4960128 | Gordon et al. | Oct 1990 | A |
| 4964408 | Hink et al. | Oct 1990 | A |
| 5041187 | Hink et al. | Aug 1991 | A |
| 5069213 | Polczynski | Dec 1991 | A |
| 5163438 | Gordon et al. | Nov 1992 | A |
| 5319355 | Russek | Jun 1994 | A |
| 5337744 | Branigan | Aug 1994 | A |
| 5341805 | Stavridi et al. | Aug 1994 | A |
| D353195 | Savage et al. | Dec 1994 | S |
| D353196 | Savage et al. | Dec 1994 | S |
| 5377676 | Vari et al. | Jan 1995 | A |
| D359546 | Savage et al. | Jun 1995 | S |
| 5431170 | Mathews | Jul 1995 | A |
| D361840 | Savage et al. | Aug 1995 | S |
| D362063 | Savage et al. | Sep 1995 | S |
| 5452717 | Branigan et al. | Sep 1995 | A |
| D363120 | Savage et al. | Oct 1995 | S |
| 5456252 | Vari et al. | Oct 1995 | A |
| 5479934 | Imran | Jan 1996 | A |
| 5482036 | Diab et al. | Jan 1996 | A |
| 5490505 | Diab et al. | Feb 1996 | A |
| 5494043 | O'Sullivan et al. | Feb 1996 | A |
| 5533511 | Kaspari et al. | Jul 1996 | A |
| 5534851 | Russek | Jul 1996 | A |
| 5561275 | Savage et al. | Oct 1996 | A |
| 5562002 | Lalin | Oct 1996 | A |
| 5590649 | Caro et al. | Jan 1997 | A |
| 5602924 | Durand et al. | Feb 1997 | A |
| 5632272 | Diab et al. | May 1997 | A |
| 5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
| 5638818 | Diab et al. | Jun 1997 | A |
| 5645440 | Tobler et al. | Jul 1997 | A |
| 5685299 | Diab et al. | Nov 1997 | A |
| D393830 | Tobler et al. | Apr 1998 | S |
| 5743262 | Lepper, Jr. et al. | Apr 1998 | A |
| 5758644 | Diab et al. | Jun 1998 | A |
| 5760910 | Lepper, Jr. et al. | Jun 1998 | A |
| 5769785 | Diab et al. | Jun 1998 | A |
| 5782757 | Diab et al. | Jul 1998 | A |
| 5785659 | Caro et al. | Jul 1998 | A |
| 5791347 | Flaherty et al. | Aug 1998 | A |
| 5810734 | Caro et al. | Sep 1998 | A |
| 5823950 | Diab et al. | Oct 1998 | A |
| 5830131 | Caro et al. | Nov 1998 | A |
| 5833618 | Caro et al. | Nov 1998 | A |
| 5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
| 5890929 | Mills et al. | Apr 1999 | A |
| 5904654 | Wohltmann et al. | May 1999 | A |
| 5919134 | Diab | Jul 1999 | A |
| 5934925 | Tobler et al. | Aug 1999 | A |
| 5940182 | Lepper, Jr. et al. | Aug 1999 | A |
| 5995855 | Kiani et al. | Nov 1999 | A |
| 5997343 | Mills et al. | Dec 1999 | A |
| 6002952 | Diab et al. | Dec 1999 | A |
| 6011986 | Diab et al. | Jan 2000 | A |
| 6027452 | Flaherty et al. | Feb 2000 | A |
| 6036642 | Diab et al. | Mar 2000 | A |
| 6045509 | Caro et al. | Apr 2000 | A |
| 6067462 | Diab et al. | May 2000 | A |
| 6081735 | Diab et al. | Jun 2000 | A |
| 6088607 | Diab et al. | Jul 2000 | A |
| 6110522 | Lepper, Jr. et al. | Aug 2000 | A |
| 6124597 | Shehada | Sep 2000 | A |
| 6128521 | Marro et al. | Oct 2000 | A |
| 6129675 | Jay | Oct 2000 | A |
| 6144868 | Parker | Nov 2000 | A |
| 6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
| 6152754 | Gerhardt et al. | Nov 2000 | A |
| 6157850 | Diab et al. | Dec 2000 | A |
| 6165005 | Mills et al. | Dec 2000 | A |
| 6184521 | Coffin, IV et al. | Feb 2001 | B1 |
| 6206830 | Diab et al. | Mar 2001 | B1 |
| 6229856 | Diab et al. | May 2001 | B1 |
| 6232609 | Snyder et al. | May 2001 | B1 |
| 6236872 | Diab et al. | May 2001 | B1 |
| 6241683 | Macklem et al. | Jun 2001 | B1 |
| 6253097 | Aronow et al. | Jun 2001 | B1 |
| 6256523 | Diab et al. | Jul 2001 | B1 |
| 6263222 | Diab et al. | Jul 2001 | B1 |
| 6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
| 6280213 | Tobler et al. | Aug 2001 | B1 |
| 6285896 | Tobler et al. | Sep 2001 | B1 |
| 6301493 | Marro et al. | Oct 2001 | B1 |
| 6317627 | Ennen et al. | Nov 2001 | B1 |
| 6321100 | Parker | Nov 2001 | B1 |
| 6325761 | Jay | Dec 2001 | B1 |
| 6334065 | Al-Ali et al. | Dec 2001 | B1 |
| 6343224 | Parker | Jan 2002 | B1 |
| 6349228 | Kiani et al. | Feb 2002 | B1 |
| 6360114 | Diab et al. | Mar 2002 | B1 |
| 6368283 | Xu et al. | Apr 2002 | B1 |
| 6371921 | Caro et al. | Apr 2002 | B1 |
| 6377829 | Al-Ali | Apr 2002 | B1 |
| 6388240 | Schulz et al. | May 2002 | B2 |
| 6397091 | Diab et al. | May 2002 | B2 |
| 6430437 | Marro | Aug 2002 | B1 |
| 6430525 | Weber et al. | Aug 2002 | B1 |
| 6463311 | Diab | Oct 2002 | B1 |
| 6470199 | Kopotic et al. | Oct 2002 | B1 |
| 6501975 | Diab et al. | Dec 2002 | B2 |
| 6505059 | Kollias et al. | Jan 2003 | B1 |
| 6515273 | Al-Ali | Feb 2003 | B2 |
| 6519487 | Parker | Feb 2003 | B1 |
| 6525386 | Mills et al. | Feb 2003 | B1 |
| 6526300 | Kiani et al. | Feb 2003 | B1 |
| 6541756 | Schulz et al. | Apr 2003 | B2 |
| 6542764 | Al-Ali et al. | Apr 2003 | B1 |
| 6580086 | Schulz et al. | Jun 2003 | B1 |
| 6584336 | Ali et al. | Jun 2003 | B1 |
| 6595316 | Cybulski et al. | Jul 2003 | B2 |
| 6597932 | Tian et al. | Jul 2003 | B2 |
| 6597933 | Kiani et al. | Jul 2003 | B2 |
| 6606511 | Ali et al. | Aug 2003 | B1 |
| 6632181 | Flaherty et al. | Oct 2003 | B2 |
| 6639668 | Trepagnier | Oct 2003 | B1 |
| 6640116 | Diab | Oct 2003 | B2 |
| 6643530 | Diab et al. | Nov 2003 | B2 |
| 6650917 | Diab et al. | Nov 2003 | B2 |
| 6654624 | Diab et al. | Nov 2003 | B2 |
| 6658276 | Kiani et al. | Dec 2003 | B2 |
| 6661161 | Lanzo et al. | Dec 2003 | B1 |
| 6671531 | Al-Ali et al. | Dec 2003 | B2 |
| 6678543 | Diab et al. | Jan 2004 | B2 |
| 6684090 | Ali et al. | Jan 2004 | B2 |
| 6684091 | Parker | Jan 2004 | B2 |
| 6697656 | Al-Ali | Feb 2004 | B1 |
| 6697657 | Shehada et al. | Feb 2004 | B1 |
| 6697658 | Al-Ali | Feb 2004 | B2 |
| RE38476 | Diab et al. | Mar 2004 | E |
| 6699194 | Diab et al. | Mar 2004 | B1 |
| 6714804 | Al-Ali et al. | Mar 2004 | B2 |
| RE38492 | Diab et al. | Apr 2004 | E |
| 6721582 | Trepagnier et al. | Apr 2004 | B2 |
| 6721585 | Parker | Apr 2004 | B1 |
| 6725075 | Al-Ali | Apr 2004 | B2 |
| 6728560 | Kollias et al. | Apr 2004 | B2 |
| 6735459 | Parker | May 2004 | B2 |
| 6745060 | Diab et al. | Jun 2004 | B2 |
| 6760607 | Al-Ali | Jul 2004 | B2 |
| 6770028 | Ali et al. | Aug 2004 | B1 |
| 6771994 | Kiani et al. | Aug 2004 | B2 |
| 6792300 | Diab et al. | Sep 2004 | B1 |
| 6813511 | Diab et al. | Nov 2004 | B2 |
| 6816741 | Diab | Nov 2004 | B2 |
| 6822564 | Al-Ali | Nov 2004 | B2 |
| 6826419 | Diab et al. | Nov 2004 | B2 |
| 6830711 | Mills et al. | Dec 2004 | B2 |
| 6850787 | Weber et al. | Feb 2005 | B2 |
| 6850788 | Al-Ali | Feb 2005 | B2 |
| 6852083 | Caro et al. | Feb 2005 | B2 |
| 6861639 | Al-Ali | Mar 2005 | B2 |
| 6898452 | Al-Ali et al. | May 2005 | B2 |
| 6920345 | Al-Ali et al. | Jul 2005 | B2 |
| 6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
| 6934570 | Kiani et al. | Aug 2005 | B2 |
| 6939305 | Flaherty et al. | Sep 2005 | B2 |
| 6943348 | Coffin, IV | Sep 2005 | B1 |
| 6950687 | Al-Ali | Sep 2005 | B2 |
| 6961598 | Diab | Nov 2005 | B2 |
| 6970792 | Diab | Nov 2005 | B1 |
| 6979812 | Al-Ali | Dec 2005 | B2 |
| 6985764 | Mason et al. | Jan 2006 | B2 |
| 6993371 | Kiani et al. | Jan 2006 | B2 |
| 6996427 | Ali et al. | Feb 2006 | B2 |
| 6999904 | Weber et al. | Feb 2006 | B2 |
| 7003338 | Weber et al. | Feb 2006 | B2 |
| 7003339 | Diab et al. | Feb 2006 | B2 |
| 7015451 | Dalke et al. | Mar 2006 | B2 |
| 7024233 | Ali et al. | Apr 2006 | B2 |
| 7027849 | Al-Ali | Apr 2006 | B2 |
| 7030749 | Al-Ali | Apr 2006 | B2 |
| 7039449 | Al-Ali | May 2006 | B2 |
| 7041060 | Flaherty et al. | May 2006 | B2 |
| 7044918 | Diab | May 2006 | B2 |
| 7067893 | Mills et al. | Jun 2006 | B2 |
| 7096052 | Mason et al. | Aug 2006 | B2 |
| 7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
| 7132641 | Schulz et al. | Nov 2006 | B2 |
| 7142901 | Kiani et al. | Nov 2006 | B2 |
| 7149561 | Diab | Dec 2006 | B2 |
| 7186966 | Al-Ali | Mar 2007 | B2 |
| 7190261 | Al-Ali | Mar 2007 | B2 |
| 7215984 | Diab | May 2007 | B2 |
| 7215986 | Diab | May 2007 | B2 |
| 7221971 | Diab | May 2007 | B2 |
| 7225006 | Al-Ali et al. | May 2007 | B2 |
| 7225007 | Al-Ali | May 2007 | B2 |
| RE39672 | Shehada et al. | Jun 2007 | E |
| 7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
| 7245953 | Parker | Jul 2007 | B1 |
| 7254429 | Schurman et al. | Aug 2007 | B2 |
| 7254431 | Al-Ali | Aug 2007 | B2 |
| 7254433 | Diab et al. | Aug 2007 | B2 |
| 7254434 | Schulz et al. | Aug 2007 | B2 |
| 7272425 | Al-Ali | Sep 2007 | B2 |
| 7274955 | Kiani et al. | Sep 2007 | B2 |
| D554263 | Al-Ali | Oct 2007 | S |
| 7280858 | Al-Ali et al. | Oct 2007 | B2 |
| 7289835 | Mansfield et al. | Oct 2007 | B2 |
| 7292883 | De Felice et al. | Nov 2007 | B2 |
| 7295866 | Al-Ali | Nov 2007 | B2 |
| 7328053 | Diab et al. | Feb 2008 | B1 |
| 7332784 | Mills et al. | Feb 2008 | B2 |
| 7340287 | Mason et al. | Mar 2008 | B2 |
| 7341559 | Schulz et al. | Mar 2008 | B2 |
| 7343186 | Lamego et al. | Mar 2008 | B2 |
| D566282 | Al-Ali et al. | Apr 2008 | S |
| 7355512 | Al-Ali | Apr 2008 | B1 |
| 7356365 | Schurman | Apr 2008 | B2 |
| 7371981 | Abdul-Hafiz | May 2008 | B2 |
| 7373193 | Al-Ali et al. | May 2008 | B2 |
| 7373194 | Weber et al. | May 2008 | B2 |
| 7376453 | Diab et al. | May 2008 | B1 |
| 7377794 | Al Ali et al. | May 2008 | B2 |
| 7377899 | Weber et al. | May 2008 | B2 |
| 7383070 | Diab et al. | Jun 2008 | B2 |
| 7415297 | Al-Ali et al. | Aug 2008 | B2 |
| 7428432 | Ali et al. | Sep 2008 | B2 |
| 7438683 | Al-Ali et al. | Oct 2008 | B2 |
| 7440787 | Diab | Oct 2008 | B2 |
| 7454240 | Diab et al. | Nov 2008 | B2 |
| 7467002 | Weber et al. | Dec 2008 | B2 |
| 7469157 | Diab et al. | Dec 2008 | B2 |
| 7471969 | Diab et al. | Dec 2008 | B2 |
| 7471971 | Diab et al. | Dec 2008 | B2 |
| 7483729 | Al-Ali et al. | Jan 2009 | B2 |
| 7483730 | Diab et al. | Jan 2009 | B2 |
| 7489958 | Diab et al. | Feb 2009 | B2 |
| 7496391 | Diab et al. | Feb 2009 | B2 |
| 7496393 | Diab et al. | Feb 2009 | B2 |
| D587657 | Al-Ali et al. | Mar 2009 | S |
| 7499741 | Diab et al. | Mar 2009 | B2 |
| 7499835 | Weber et al. | Mar 2009 | B2 |
| 7500950 | Al-Ali et al. | Mar 2009 | B2 |
| 7509154 | Diab et al. | Mar 2009 | B2 |
| 7509494 | Al-Ali | Mar 2009 | B2 |
| 7510849 | Schurman et al. | Mar 2009 | B2 |
| 7526328 | Diab et al. | Apr 2009 | B2 |
| 7530942 | Diab | May 2009 | B1 |
| 7530949 | Al Ali et al. | May 2009 | B2 |
| 7530955 | Diab et al. | May 2009 | B2 |
| 7563110 | Al-Ali et al. | Jul 2009 | B2 |
| 7596398 | Al-Ali et al. | Sep 2009 | B2 |
| 7618375 | Flaherty | Nov 2009 | B2 |
| D606659 | Kiani et al. | Dec 2009 | S |
| 7647083 | Al-Ali et al. | Jan 2010 | B2 |
| D609193 | Al-Ali et al. | Feb 2010 | S |
| D614305 | Al-Ali et al. | Apr 2010 | S |
| RE41317 | Parker | May 2010 | E |
| 7729733 | Al-Ali et al. | Jun 2010 | B2 |
| 7734320 | Al-Ali | Jun 2010 | B2 |
| 7761127 | Al-Ali et al. | Jul 2010 | B2 |
| 7761128 | Al-Ali et al. | Jul 2010 | B2 |
| 7764982 | Dalke et al. | Jul 2010 | B2 |
| D621516 | Kiani et al. | Aug 2010 | S |
| 7791155 | Diab | Sep 2010 | B2 |
| 7801581 | Diab | Sep 2010 | B2 |
| 7822452 | Schurman et al. | Oct 2010 | B2 |
| RE41912 | Parker | Nov 2010 | E |
| 7844313 | Kiani et al. | Nov 2010 | B2 |
| 7844314 | Al-Ali | Nov 2010 | B2 |
| 7844315 | Al-Ali | Nov 2010 | B2 |
| 7865222 | Weber et al. | Jan 2011 | B2 |
| 7873497 | Weber et al. | Jan 2011 | B2 |
| 7880606 | Al-Ali | Feb 2011 | B2 |
| 7880626 | Al-Ali et al. | Feb 2011 | B2 |
| 7891355 | Al-Ali et al. | Feb 2011 | B2 |
| 7894868 | Al-Ali et al. | Feb 2011 | B2 |
| 7899507 | Al-Ali et al. | Mar 2011 | B2 |
| 7899518 | Trepagnier et al. | Mar 2011 | B2 |
| 7904132 | Weber et al. | Mar 2011 | B2 |
| 7909772 | Popov et al. | Mar 2011 | B2 |
| 7910875 | Al-Ali | Mar 2011 | B2 |
| 7919713 | Al-Ali et al. | Apr 2011 | B2 |
| 7937128 | Al-Ali | May 2011 | B2 |
| 7937129 | Mason et al. | May 2011 | B2 |
| 7937130 | Diab et al. | May 2011 | B2 |
| 7941199 | Kiani | May 2011 | B2 |
| 7951086 | Flaherty et al. | May 2011 | B2 |
| 7957780 | Lamego et al. | Jun 2011 | B2 |
| 7962188 | Kiani et al. | Jun 2011 | B2 |
| 7962190 | Diab et al. | Jun 2011 | B1 |
| 7976472 | Kiani | Jul 2011 | B2 |
| 7988637 | Diab | Aug 2011 | B2 |
| 7990382 | Kiani | Aug 2011 | B2 |
| 7991446 | Ali et al. | Aug 2011 | B2 |
| 8000761 | Al-Ali | Aug 2011 | B2 |
| 8008088 | Bellott et al. | Aug 2011 | B2 |
| RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
| 8019400 | Diab et al. | Sep 2011 | B2 |
| 8028701 | Al-Ali et al. | Oct 2011 | B2 |
| 8029765 | Bellott et al. | Oct 2011 | B2 |
| 8036727 | Schurman et al. | Oct 2011 | B2 |
| 8036728 | Diab et al. | Oct 2011 | B2 |
| 8046040 | Ali et al. | Oct 2011 | B2 |
| 8046041 | Diab et al. | Oct 2011 | B2 |
| 8046042 | Diab et al. | Oct 2011 | B2 |
| 8048040 | Kiani | Nov 2011 | B2 |
| 8050728 | Al-Ali et al. | Nov 2011 | B2 |
| RE43169 | Parker | Feb 2012 | E |
| 8118620 | Al-Ali et al. | Feb 2012 | B2 |
| 8126528 | Diab et al. | Feb 2012 | B2 |
| 8128572 | Diab et al. | Mar 2012 | B2 |
| 8130105 | Al-Ali et al. | Mar 2012 | B2 |
| 8145287 | Diab et al. | Mar 2012 | B2 |
| 8150487 | Diab et al. | Apr 2012 | B2 |
| 8175672 | Parker | May 2012 | B2 |
| 8180420 | Diab et al. | May 2012 | B2 |
| 8182443 | Kiani | May 2012 | B1 |
| 8185180 | Diab et al. | May 2012 | B2 |
| 8190223 | Al-Ali et al. | May 2012 | B2 |
| 8190227 | Diab et al. | May 2012 | B2 |
| 8203438 | Kiani et al. | Jun 2012 | B2 |
| 8203704 | Merritt et al. | Jun 2012 | B2 |
| 8204566 | Schurman et al. | Jun 2012 | B2 |
| 8219172 | Schurman et al. | Jul 2012 | B2 |
| 8224411 | Al-Ali et al. | Jul 2012 | B2 |
| 8228181 | Al-Ali | Jul 2012 | B2 |
| 8229533 | Diab et al. | Jul 2012 | B2 |
| 8233955 | Al-Ali et al. | Jul 2012 | B2 |
| 8244325 | Al-Ali et al. | Aug 2012 | B2 |
| 8255026 | Al-Ali | Aug 2012 | B1 |
| 8255027 | Al-Ali et al. | Aug 2012 | B2 |
| 8255028 | Al-Ali et al. | Aug 2012 | B2 |
| 8260577 | Weber et al. | Sep 2012 | B2 |
| 8265723 | McHale et al. | Sep 2012 | B1 |
| 8274360 | Sampath et al. | Sep 2012 | B2 |
| 8301217 | Al-Ali et al. | Oct 2012 | B2 |
| 8306596 | Schurman et al. | Nov 2012 | B2 |
| 8310336 | Muhsin et al. | Nov 2012 | B2 |
| 8315683 | Al-Ali et al. | Nov 2012 | B2 |
| RE43860 | Parker | Dec 2012 | E |
| 8337403 | Al-Ali et al. | Dec 2012 | B2 |
| 8346330 | Lamego | Jan 2013 | B2 |
| 8353842 | Al-Ali et al. | Jan 2013 | B2 |
| 8355766 | MacNeish, III et al. | Jan 2013 | B2 |
| 8359080 | Diab et al. | Jan 2013 | B2 |
| 8364223 | Al-Ali et al. | Jan 2013 | B2 |
| 8364226 | Diab et al. | Jan 2013 | B2 |
| 8374665 | Lamego | Feb 2013 | B2 |
| 8385995 | Al-Ali et al. | Feb 2013 | B2 |
| 8385996 | Smith et al. | Feb 2013 | B2 |
| 8388353 | Kiani | Mar 2013 | B2 |
| 8399822 | Al-Ali | Mar 2013 | B2 |
| 8401602 | Kiani | Mar 2013 | B2 |
| 8405608 | Al-Ali et al. | Mar 2013 | B2 |
| 8414499 | Al-Ali et al. | Apr 2013 | B2 |
| 8418524 | Al-Ali | Apr 2013 | B2 |
| 8423106 | Lamego et al. | Apr 2013 | B2 |
| 8428967 | Olsen et al. | Apr 2013 | B2 |
| 8430817 | Al-Ali et al. | Apr 2013 | B1 |
| 8437825 | Dalvi et al. | May 2013 | B2 |
| 8455290 | Siskavich | Jun 2013 | B2 |
| 8457703 | Al-Ali | Jun 2013 | B2 |
| 8457707 | Kiani | Jun 2013 | B2 |
| 8463349 | Diab et al. | Jun 2013 | B2 |
| 8466286 | Bellot et al. | Jun 2013 | B2 |
| 8471713 | Poeze et al. | Jun 2013 | B2 |
| 8473020 | Kiani et al. | Jun 2013 | B2 |
| 8483787 | Al-Ali et al. | Jul 2013 | B2 |
| 8489364 | Weber et al. | Jul 2013 | B2 |
| 8498684 | Weber et al. | Jul 2013 | B2 |
| 8504128 | Blank et al. | Aug 2013 | B2 |
| 8509867 | Workman et al. | Aug 2013 | B2 |
| 8515509 | Bruinsma et al. | Aug 2013 | B2 |
| 8523781 | Al-Ali | Sep 2013 | B2 |
| 8529301 | Al-Ali et al. | Sep 2013 | B2 |
| 8532727 | Ali et al. | Sep 2013 | B2 |
| 8532728 | Diab et al. | Sep 2013 | B2 |
| D692145 | Al-Ali et al. | Oct 2013 | S |
| 8547209 | Kiani et al. | Oct 2013 | B2 |
| 8548548 | Al-Ali | Oct 2013 | B2 |
| 8548549 | Schurman et al. | Oct 2013 | B2 |
| 8548550 | Al-Ali et al. | Oct 2013 | B2 |
| 8560032 | Al-Ali et al. | Oct 2013 | B2 |
| 8560034 | Diab et al. | Oct 2013 | B1 |
| 8570167 | Al-Ali | Oct 2013 | B2 |
| 8570503 | Vo et al. | Oct 2013 | B2 |
| 8571617 | Reichgott et al. | Oct 2013 | B2 |
| 8571618 | Lamego et al. | Oct 2013 | B1 |
| 8571619 | Al-Ali et al. | Oct 2013 | B2 |
| 8577431 | Lamego et al. | Nov 2013 | B2 |
| 8581732 | Al-Ali et al. | Nov 2013 | B2 |
| 8584345 | Al-Ali et al. | Nov 2013 | B2 |
| 8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
| 8600467 | Al-Ali et al. | Dec 2013 | B2 |
| 8606342 | Diab | Dec 2013 | B2 |
| 8626255 | Al-Ali et al. | Jan 2014 | B2 |
| 8630691 | Lamego et al. | Jan 2014 | B2 |
| 8634889 | Al-Ali et al. | Jan 2014 | B2 |
| 8641631 | Sierra et al. | Feb 2014 | B2 |
| 8652060 | Al-Ali | Feb 2014 | B2 |
| 8663107 | Kiani | Mar 2014 | B2 |
| 8666468 | Al-Ali | Mar 2014 | B1 |
| 8667967 | Al- Ali et al. | Mar 2014 | B2 |
| 8670811 | O'Reilly | Mar 2014 | B2 |
| 8670814 | Diab et al. | Mar 2014 | B2 |
| 8676286 | Weber et al. | Mar 2014 | B2 |
| 8682407 | Al-Ali | Mar 2014 | B2 |
| RE44823 | Parker | Apr 2014 | E |
| RE44875 | Kiani et al. | Apr 2014 | E |
| 8690799 | Telfort et al. | Apr 2014 | B2 |
| 8700112 | Kiani | Apr 2014 | B2 |
| 8702627 | Telfort et al. | Apr 2014 | B2 |
| 8706179 | Parker | Apr 2014 | B2 |
| 8712494 | MacNeish, III et al. | Apr 2014 | B1 |
| 8715206 | Telfort et al. | May 2014 | B2 |
| 8718735 | Lamego et al. | May 2014 | B2 |
| 8718737 | Diab et al. | May 2014 | B2 |
| 8718738 | Blank et al. | May 2014 | B2 |
| 8720249 | Al-Ali | May 2014 | B2 |
| 8721541 | Al-Ali et al. | May 2014 | B2 |
| 8721542 | Al-Ali et al. | May 2014 | B2 |
| 8723677 | Kiani | May 2014 | B1 |
| 8740792 | Kiani et al. | Jun 2014 | B1 |
| 8754776 | Poeze et al. | Jun 2014 | B2 |
| 8755535 | Telfort et al. | Jun 2014 | B2 |
| 8755856 | Diab et al. | Jun 2014 | B2 |
| 8755872 | Marinow | Jun 2014 | B1 |
| 8761850 | Lamego | Jun 2014 | B2 |
| 8764671 | Kiani | Jul 2014 | B2 |
| 8768423 | Shakespeare et al. | Jul 2014 | B2 |
| 8771204 | Telfort et al. | Jul 2014 | B2 |
| 8777634 | Kiani et al. | Jul 2014 | B2 |
| 8781543 | Diab et al. | Jul 2014 | B2 |
| 8781544 | Al-Ali et al. | Jul 2014 | B2 |
| 8781549 | Al-Ali et al. | Jul 2014 | B2 |
| 8788003 | Schurman et al. | Jul 2014 | B2 |
| 8790268 | Al-Ali | Jul 2014 | B2 |
| 8801613 | Al-Ali et al. | Aug 2014 | B2 |
| 8821397 | Al-Ali et al. | Sep 2014 | B2 |
| 8821415 | Al-Ali et al. | Sep 2014 | B2 |
| 8830449 | Lamego et al. | Sep 2014 | B1 |
| 8831700 | Schurman et al. | Sep 2014 | B2 |
| 8840549 | Al-Ali et al. | Sep 2014 | B2 |
| 8847740 | Kiani et al. | Sep 2014 | B2 |
| 8849365 | Smith et al. | Sep 2014 | B2 |
| 8852094 | Al-Ali et al. | Oct 2014 | B2 |
| 8852994 | Wojtczuk et al. | Oct 2014 | B2 |
| 8868147 | Stippick et al. | Oct 2014 | B2 |
| 8868150 | Al-Ali et al. | Oct 2014 | B2 |
| 8870792 | Al-Ali et al. | Oct 2014 | B2 |
| 8886271 | Kiani et al. | Nov 2014 | B2 |
| 8888539 | Al-Ali et al. | Nov 2014 | B2 |
| 8888708 | Diab et al. | Nov 2014 | B2 |
| 8892180 | Weber et al. | Nov 2014 | B2 |
| 8897847 | Al-Ali | Nov 2014 | B2 |
| 8909310 | Lamego et al. | Dec 2014 | B2 |
| 8911377 | Al-Ali | Dec 2014 | B2 |
| 8912909 | Al-Ali et al. | Dec 2014 | B2 |
| 8920317 | Al-Ali et al. | Dec 2014 | B2 |
| 8921699 | Al-Ali et al. | Dec 2014 | B2 |
| 8922382 | Al-Ali et al. | Dec 2014 | B2 |
| 8929964 | Al-Ali et al. | Jan 2015 | B2 |
| 8942777 | Diab et al. | Jan 2015 | B2 |
| 8948834 | Diab et al. | Feb 2015 | B2 |
| 8948835 | Diab | Feb 2015 | B2 |
| 8965471 | Lamego | Feb 2015 | B2 |
| 8983564 | Al-Ali | Mar 2015 | B2 |
| 8989831 | Al-Ali et al. | Mar 2015 | B2 |
| 8996085 | Kiani et al. | Mar 2015 | B2 |
| 8998809 | Kiani | Apr 2015 | B2 |
| 9028429 | Telfort et al. | May 2015 | B2 |
| 9037207 | Al-Ali et al. | May 2015 | B2 |
| 9060721 | Reichgott et al. | Jun 2015 | B2 |
| 9066666 | Kiani | Jun 2015 | B2 |
| 9066680 | Al-Ali et al. | Jun 2015 | B1 |
| 9072474 | Al-Ali et al. | Jul 2015 | B2 |
| 9078560 | Schurman et al. | Jul 2015 | B2 |
| 9084569 | Weber et al. | Jul 2015 | B2 |
| 9095316 | Welch et al. | Aug 2015 | B2 |
| 9106038 | Telfort et al. | Aug 2015 | B2 |
| 9107625 | Telfort et al. | Aug 2015 | B2 |
| 9107626 | Al-Ali et al. | Aug 2015 | B2 |
| 9113831 | Al-Ali | Aug 2015 | B2 |
| 9113832 | Al-Ali | Aug 2015 | B2 |
| 9119595 | Lamego | Sep 2015 | B2 |
| 9131881 | Diab et al. | Sep 2015 | B2 |
| 9131882 | Al-Ali et al. | Sep 2015 | B2 |
| 9131883 | Al-Ali | Sep 2015 | B2 |
| 9131917 | Telfort et al. | Sep 2015 | B2 |
| 9138180 | Coverston et al. | Sep 2015 | B1 |
| 9138182 | Al-Ali et al. | Sep 2015 | B2 |
| 9138192 | Weber et al. | Sep 2015 | B2 |
| 9142117 | Muhsin et al. | Sep 2015 | B2 |
| 9153112 | Kiani et al. | Oct 2015 | B1 |
| 9153121 | Kiani et al. | Oct 2015 | B2 |
| 9161696 | Al-Ali et al. | Oct 2015 | B2 |
| 9161713 | Al-Ali et al. | Oct 2015 | B2 |
| 9167995 | Lamego et al. | Oct 2015 | B2 |
| 9176141 | Al-Ali et al. | Nov 2015 | B2 |
| 9186102 | Bruinsma et al. | Nov 2015 | B2 |
| 9192312 | Al-Ali | Nov 2015 | B2 |
| 9192329 | Al-Ali | Nov 2015 | B2 |
| 9192351 | Telfort et al. | Nov 2015 | B1 |
| 9195385 | Al-Ali et al. | Nov 2015 | B2 |
| 9211072 | Kiani | Dec 2015 | B2 |
| 9211095 | Al-Ali | Dec 2015 | B1 |
| 9218454 | Kiani et al. | Dec 2015 | B2 |
| 9226696 | Kiani | Jan 2016 | B2 |
| 9241662 | Al-Ali et al. | Jan 2016 | B2 |
| 9245668 | Vo et al. | Jan 2016 | B1 |
| 9259185 | Abdul-Hafiz et al. | Feb 2016 | B2 |
| 9267572 | Barker et al. | Feb 2016 | B2 |
| 9277880 | Poeze et al. | Mar 2016 | B2 |
| 9289167 | Diab et al. | Mar 2016 | B2 |
| 9295421 | Kiani et al. | Mar 2016 | B2 |
| 9307928 | Al-Ali et al. | Apr 2016 | B1 |
| 9323894 | Kiani | Apr 2016 | B2 |
| D755392 | Hwang et al. | May 2016 | S |
| 9326712 | Kiani | May 2016 | B1 |
| 9333316 | Kiani | May 2016 | B2 |
| 9339220 | Lamego et al. | May 2016 | B2 |
| 9341565 | Lamego et al. | May 2016 | B2 |
| 9351673 | Diab et al. | May 2016 | B2 |
| 9351675 | Al-Ali et al. | May 2016 | B2 |
| 9364181 | Kiani et al. | Jun 2016 | B2 |
| 9368671 | Wojtczuk et al. | Jun 2016 | B2 |
| 9370325 | Al-Ali et al. | Jun 2016 | B2 |
| 9370326 | McHale et al. | Jun 2016 | B2 |
| 9370335 | Al-Ali et al. | Jun 2016 | B2 |
| 9375185 | Ali et al. | Jun 2016 | B2 |
| 9386953 | Al-Ali | Jul 2016 | B2 |
| 9386961 | Al-Ali et al. | Jul 2016 | B2 |
| 9392945 | Al-Ali et al. | Jul 2016 | B2 |
| 9397448 | Al-Ali et al. | Jul 2016 | B2 |
| 9408542 | Kinast | Aug 2016 | B1 |
| 9436645 | Al-Ali et al. | Sep 2016 | B2 |
| 9445759 | Lamego et al. | Sep 2016 | B1 |
| 9466919 | Kiani et al. | Oct 2016 | B2 |
| 9474474 | Lamego et al. | Oct 2016 | B2 |
| 9480422 | Al-Ali | Nov 2016 | B2 |
| 9480435 | Olsen | Nov 2016 | B2 |
| 9492110 | Al-Ali et al. | Nov 2016 | B2 |
| 9510779 | Poeze et al. | Dec 2016 | B2 |
| 9517024 | Kiani et al. | Dec 2016 | B2 |
| 9532722 | Lamego et al. | Jan 2017 | B2 |
| 9538949 | Al-Ali et al. | Jan 2017 | B2 |
| 9538980 | Telfort et al. | Jan 2017 | B2 |
| 9549696 | Lamego et al. | Jan 2017 | B2 |
| 9554737 | Schurman et al. | Jan 2017 | B2 |
| 9560996 | Kiani | Feb 2017 | B2 |
| 9560998 | Al-Ali et al. | Feb 2017 | B2 |
| 9566019 | Al-Ali et al. | Feb 2017 | B2 |
| 9579039 | Jansen et al. | Feb 2017 | B2 |
| 9591975 | Dalvi et al. | Mar 2017 | B2 |
| 9622693 | Diab | Apr 2017 | B2 |
| 20030018248 | Kreger | Jan 2003 | A1 |
| 20030171661 | Tong | Sep 2003 | A1 |
| 20070282478 | Al-Ali et al. | Dec 2007 | A1 |
| 20090247984 | Lamego et al. | Oct 2009 | A1 |
| 20090275813 | Davis | Nov 2009 | A1 |
| 20090275844 | Al-Ali | Nov 2009 | A1 |
| 20100004518 | Vo et al. | Jan 2010 | A1 |
| 20100030040 | Poeze et al. | Feb 2010 | A1 |
| 20100060350 | Zhang | Mar 2010 | A1 |
| 20110082711 | Poeze et al. | Apr 2011 | A1 |
| 20110087083 | Poeze et al. | Apr 2011 | A1 |
| 20110105854 | Kiani et al. | May 2011 | A1 |
| 20110125060 | Telfort et al. | May 2011 | A1 |
| 20110208015 | Welch et al. | Aug 2011 | A1 |
| 20110213212 | Al-Ali | Sep 2011 | A1 |
| 20110230733 | Al-Ali | Sep 2011 | A1 |
| 20110237969 | Eckerbom et al. | Sep 2011 | A1 |
| 20110288383 | Diab | Nov 2011 | A1 |
| 20110301444 | Al-Ali | Dec 2011 | A1 |
| 20120041316 | Al-Ali et al. | Feb 2012 | A1 |
| 20120046557 | Kiani | Feb 2012 | A1 |
| 20120059267 | Lamego et al. | Mar 2012 | A1 |
| 20120088984 | Al-Ali et al. | Apr 2012 | A1 |
| 20120165629 | Merritt et al. | Jun 2012 | A1 |
| 20120179006 | Jansen et al. | Jul 2012 | A1 |
| 20120209082 | Al-Ali | Aug 2012 | A1 |
| 20120209084 | Olsen et al. | Aug 2012 | A1 |
| 20120283524 | Kiani et al. | Nov 2012 | A1 |
| 20120296178 | Lamego et al. | Nov 2012 | A1 |
| 20120319816 | Al-Ali | Dec 2012 | A1 |
| 20120330112 | Lamego et al. | Dec 2012 | A1 |
| 20130023775 | Lamego et al. | Jan 2013 | A1 |
| 20130041591 | Lamego | Feb 2013 | A1 |
| 20130046204 | Lamego et al. | Feb 2013 | A1 |
| 20130060147 | Welch et al. | Mar 2013 | A1 |
| 20130096405 | Garfio | Apr 2013 | A1 |
| 20130096936 | Sampath et al. | Apr 2013 | A1 |
| 20130190581 | Al-Ali et al. | Jul 2013 | A1 |
| 20130211214 | Olsen | Aug 2013 | A1 |
| 20130243021 | Siskavich | Sep 2013 | A1 |
| 20130253334 | Al-Ali et al. | Sep 2013 | A1 |
| 20130262730 | Al-Ali et al. | Oct 2013 | A1 |
| 20130267804 | Al-Ali | Oct 2013 | A1 |
| 20130274572 | Al-Ali et al. | Oct 2013 | A1 |
| 20130296672 | O'Neil et al. | Nov 2013 | A1 |
| 20130296713 | Al-Ali et al. | Nov 2013 | A1 |
| 20130317370 | Dalvi et al. | Nov 2013 | A1 |
| 20130324808 | Al-Ali et al. | Dec 2013 | A1 |
| 20130331660 | Al-Ali et al. | Dec 2013 | A1 |
| 20130331670 | Kiani | Dec 2013 | A1 |
| 20140012100 | Al-Ali et al. | Jan 2014 | A1 |
| 20140034353 | Al-Ali et al. | Feb 2014 | A1 |
| 20140051953 | Lamego et al. | Feb 2014 | A1 |
| 20140066783 | Kiani et al. | Mar 2014 | A1 |
| 20140077956 | Sampath et al. | Mar 2014 | A1 |
| 20140081100 | Muhsin et al. | Mar 2014 | A1 |
| 20140081175 | Telfort | Mar 2014 | A1 |
| 20140094667 | Schurman et al. | Apr 2014 | A1 |
| 20140100434 | Diab et al. | Apr 2014 | A1 |
| 20140114199 | Lamego et al. | Apr 2014 | A1 |
| 20140120564 | Workman et al. | May 2014 | A1 |
| 20140121482 | Merritt et al. | May 2014 | A1 |
| 20140121483 | Kiani | May 2014 | A1 |
| 20140127137 | Bellott et al. | May 2014 | A1 |
| 20140129702 | Lamego et al. | May 2014 | A1 |
| 20140135588 | Al-Ali et al. | May 2014 | A1 |
| 20140142401 | Al-Ali et al. | May 2014 | A1 |
| 20140163344 | Al-Ali | Jun 2014 | A1 |
| 20140163402 | Lamego et al. | Jun 2014 | A1 |
| 20140166076 | Kiani et al. | Jun 2014 | A1 |
| 20140171763 | Diab | Jun 2014 | A1 |
| 20140180038 | Kiani | Jun 2014 | A1 |
| 20140180154 | Sierra et al. | Jun 2014 | A1 |
| 20140180160 | Brown et al. | Jun 2014 | A1 |
| 20140187973 | Brown et al. | Jul 2014 | A1 |
| 20140194766 | Al-Ali et al. | Jul 2014 | A1 |
| 20140206963 | Al-Ali | Jul 2014 | A1 |
| 20140213864 | Abdul-Hafiz et al. | Jul 2014 | A1 |
| 20140266790 | Al-Ali et al. | Sep 2014 | A1 |
| 20140275808 | Poeze et al. | Sep 2014 | A1 |
| 20140275835 | Lamego et al. | Sep 2014 | A1 |
| 20140275871 | Lamego et al. | Sep 2014 | A1 |
| 20140275872 | Merritt et al. | Sep 2014 | A1 |
| 20140275881 | Lamego et al. | Sep 2014 | A1 |
| 20140276115 | Dalvi et al. | Sep 2014 | A1 |
| 20140288400 | Diab et al. | Sep 2014 | A1 |
| 20140303520 | Telfort et al. | Oct 2014 | A1 |
| 20140316217 | Purdon et al. | Oct 2014 | A1 |
| 20140316218 | Purdon et al. | Oct 2014 | A1 |
| 20140316228 | Blank et al. | Oct 2014 | A1 |
| 20140323825 | Al-Ali et al. | Oct 2014 | A1 |
| 20140323897 | Brown et al. | Oct 2014 | A1 |
| 20140323898 | Purdon et al. | Oct 2014 | A1 |
| 20140330092 | Al-Ali et al. | Nov 2014 | A1 |
| 20140330098 | Merritt et al. | Nov 2014 | A1 |
| 20140330099 | Al-Ali et al. | Nov 2014 | A1 |
| 20140336481 | Shakespeare et al. | Nov 2014 | A1 |
| 20140357966 | Al-Ali et al. | Dec 2014 | A1 |
| 20140371548 | Al-Ali et al. | Dec 2014 | A1 |
| 20140371632 | Al-Ali et al. | Dec 2014 | A1 |
| 20140378784 | Kiani et al. | Dec 2014 | A1 |
| 20150005600 | Blank et al. | Jan 2015 | A1 |
| 20150011907 | Purdon et al. | Jan 2015 | A1 |
| 20150012231 | Poeze et al. | Jan 2015 | A1 |
| 20150018650 | Al-Ali et al. | Jan 2015 | A1 |
| 20150025406 | Al-Ali | Jan 2015 | A1 |
| 20150032029 | Al-Ali et al. | Jan 2015 | A1 |
| 20150038859 | Dalvi et al. | Feb 2015 | A1 |
| 20150045637 | Dalvi | Feb 2015 | A1 |
| 20150051462 | Olsen | Feb 2015 | A1 |
| 20150080754 | Purdon et al. | Mar 2015 | A1 |
| 20150087936 | Al-Ali et al. | Mar 2015 | A1 |
| 20150094546 | Al-Ali | Apr 2015 | A1 |
| 20150097701 | Al-Ali et al. | Apr 2015 | A1 |
| 20150099950 | Al-Ali et al. | Apr 2015 | A1 |
| 20150099951 | Al-Ali et al. | Apr 2015 | A1 |
| 20150099955 | Al-Ali et al. | Apr 2015 | A1 |
| 20150101844 | Al-Ali et al. | Apr 2015 | A1 |
| 20150106121 | Muhsin et al. | Apr 2015 | A1 |
| 20150112151 | Muhsin et al. | Apr 2015 | A1 |
| 20150116076 | Al-Ali et al. | Apr 2015 | A1 |
| 20150126830 | Schurman et al. | May 2015 | A1 |
| 20150133755 | Smith et al. | May 2015 | A1 |
| 20150140863 | Al-Ali et al. | May 2015 | A1 |
| 20150141781 | Weber et al. | May 2015 | A1 |
| 20150165312 | Kiani | Jun 2015 | A1 |
| 20150196237 | Lamego | Jul 2015 | A1 |
| 20150201874 | Diab | Jul 2015 | A1 |
| 20150208966 | Al-Ali | Jul 2015 | A1 |
| 20150216459 | Al-Ali et al. | Aug 2015 | A1 |
| 20150230755 | Al-Ali et al. | Aug 2015 | A1 |
| 20150238722 | Al-Ali | Aug 2015 | A1 |
| 20150245773 | Lamego et al. | Sep 2015 | A1 |
| 20150245794 | Al-Ali | Sep 2015 | A1 |
| 20150257689 | Al-Ali et al. | Sep 2015 | A1 |
| 20150272514 | Kiani et al. | Oct 2015 | A1 |
| 20150351697 | Weber et al. | Dec 2015 | A1 |
| 20150351704 | Kiani et al. | Dec 2015 | A1 |
| 20150359429 | Al-Ali et al. | Dec 2015 | A1 |
| 20150366472 | Kiani | Dec 2015 | A1 |
| 20150366507 | Blank | Dec 2015 | A1 |
| 20150374298 | Al-Ali et al. | Dec 2015 | A1 |
| 20150380875 | Coverston et al. | Dec 2015 | A1 |
| 20160000362 | Diab et al. | Jan 2016 | A1 |
| 20160007930 | Weber et al. | Jan 2016 | A1 |
| 20160029932 | Al-Ali | Feb 2016 | A1 |
| 20160029933 | Al-Ali et al. | Feb 2016 | A1 |
| 20160045118 | Kiani | Feb 2016 | A1 |
| 20160051205 | Al-Ali et al. | Feb 2016 | A1 |
| 20160058338 | Schurman et al. | Mar 2016 | A1 |
| 20160058347 | Reichgott et al. | Mar 2016 | A1 |
| 20160066823 | Kind et al. | Mar 2016 | A1 |
| 20160066824 | Al-Ali et al. | Mar 2016 | A1 |
| 20160066879 | Telfort et al. | Mar 2016 | A1 |
| 20160072429 | Kiani et al. | Mar 2016 | A1 |
| 20160073967 | Lamego et al. | Mar 2016 | A1 |
| 20160081552 | Wojtczuk et al. | Mar 2016 | A1 |
| 20160095543 | Telfort et al. | Apr 2016 | A1 |
| 20160095548 | Al-Ali et al. | Apr 2016 | A1 |
| 20160103598 | Al-Ali et al. | Apr 2016 | A1 |
| 20160113527 | Al-Ali et al. | Apr 2016 | A1 |
| 20160143548 | Al-Ali | May 2016 | A1 |
| 20160166183 | Poeze et al. | Jun 2016 | A1 |
| 20160166188 | Bruinsma et al. | Jun 2016 | A1 |
| 20160166210 | Al-Ali | Jun 2016 | A1 |
| 20160192869 | Kiani et al. | Jul 2016 | A1 |
| 20160196388 | Lamego | Jul 2016 | A1 |
| 20160197436 | Barker et al. | Jul 2016 | A1 |
| 20160213281 | Eckerbom et al. | Jul 2016 | A1 |
| 20160228043 | O'Neil et al. | Aug 2016 | A1 |
| 20160233632 | Scruggs et al. | Aug 2016 | A1 |
| 20160234944 | Schmidt et al. | Aug 2016 | A1 |
| 20160270735 | Diab et al. | Sep 2016 | A1 |
| 20160283665 | Sampath et al. | Sep 2016 | A1 |
| 20160287090 | Al-Ali et al. | Oct 2016 | A1 |
| 20160287786 | Kiani | Oct 2016 | A1 |
| 20160296169 | McHale et al. | Oct 2016 | A1 |
| 20160310052 | Al-Ali et al. | Oct 2016 | A1 |
| 20160314260 | Kiani | Oct 2016 | A1 |
| 20160324486 | Al-Ali et al. | Nov 2016 | A1 |
| 20160324488 | Olsen | Nov 2016 | A1 |
| 20160327984 | Al-Ali et al. | Nov 2016 | A1 |
| 20160328528 | Al-Ali et al. | Nov 2016 | A1 |
| 20160331332 | Al-Ali | Nov 2016 | A1 |
| 20160367173 | Dalvi et al. | Dec 2016 | A1 |
| 20170007134 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007190 | Al-Ali et al. | Jan 2017 | A1 |
| 20170007198 | Al-Ali et al. | Jan 2017 | A1 |
| 20170014084 | Al-Ali et al. | Jan 2017 | A1 |
| 20170021099 | Al-Ali et al. | Jan 2017 | A1 |
| 20170027456 | Kinast et al. | Feb 2017 | A1 |
| 20170042488 | Muhsin | Feb 2017 | A1 |
| 20170055847 | Kiani et al. | Mar 2017 | A1 |
| 20170055851 | Al-Ali | Mar 2017 | A1 |
| 20170055882 | Al-Ali et al. | Mar 2017 | A1 |
| 20170055887 | Al-Ali | Mar 2017 | A1 |
| 20170055896 | Al-Ali et al. | Mar 2017 | A1 |
| 20170079594 | Telfort et al. | Mar 2017 | A1 |
| 20170086723 | Al-Ali et al. | Mar 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| WO 2011039580 | Apr 2011 | WO |
| Entry |
|---|
| US 8,845,543, 09/2014, Diab et al. (withdrawn) |
| US 9,579,050, 02/2017, Al-Ali (withdrawn) |
| Number | Date | Country | |
|---|---|---|---|
| 20170027456 A1 | Feb 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61366862 | Jul 2010 | US | |
| 61469511 | Mar 2011 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13189396 | Jul 2011 | US |
| Child | 15229840 | US |
